paclitaxel has been researched along with Recrudescence in 328 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 29 (8.84) | 18.2507 |
| 2000's | 91 (27.74) | 29.6817 |
| 2010's | 190 (57.93) | 24.3611 |
| 2020's | 18 (5.49) | 2.80 |
| Authors | Studies |
|---|---|
| Garvey, DS; Janero, DR; Letts, LG; Lin, CE; Marek, P; Richardson, SK; Serebryanik, D; Shumway, MJ; Tam, SW; Trocha, AM; Young, DV | 1 |
| Aube-Peterkin, M; Brandes, SB; Cantrill, CH; Carrier, S; Chevli, K; Coutinho, K; D'Anna, R; Dann, J; DeLong, JM; DeSouza, E; DiMarco, D; Ehlert, MJ; Elliott, SP; Erickson, BA; Hagedorn, JC; Husmann, DA; Levin, R; Morey, A; Natale, R; Olsson, C; Robertson, KJ; Schlaifer, A; Te, AE; Virasoro, R | 1 |
| Asada, Y; Honda, Y; Nishihira, K; Shibata, Y | 1 |
| Armstrong, DK; Arranz, JA; Coleman, RL; Fujiwara, K; Gabra, H; Ghamande, SA; González-Martín, A; Hanna, R; Herzog, TJ; Jia, Y; Monk, BJ; Pignata, S; Ramsay, L; Rubio, MJ; Scambia, G; Sehouli, J; Slomovitz, B; Tewari, KS; Ushijima, K; Vergote, IB; Vulsteke, C; Weil, SC; Wenham, RM; Zamagni, C | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, JS; Kim, KH; Kim, M; Kim, SH; Kim, TM; Kim, YJ; Lee, JS; Ock, CY; Song, S | 1 |
| Aoki, D; Arai, M; Mizuno, M; Nakai, H; Nakanishi, T; Nishio, S; Nomura, H; Susumu, N; Takehara, K; Tokunaga, H; Watanabe, Y; Yaegashi, N; Yokoyama, Y | 1 |
| Alvandi, B; Armstrong, EJ; Behan, S; Foley, TR; Giannopoulos, S; Hossain, P; Jawaid, O; Kokkinidis, DG; Singh, GD; Waldo, SW | 1 |
| Carnevale, M; Garg, K; Lipsitz, EC; Phair, J; Scher, L; Shariff, S | 1 |
| Bosiers, M; Callaert, J; De Donato, G; Deloose, K; Eckstein, HH; Giaquinta, A; Hendriks, J; Keirse, K; Maene, L; Navarro, T; Scheinert, D; Setacci, C; Silveira, PG; Teβarek, J; Torsello, G; Veroux, P; Wauters, J | 1 |
| Banyai, M; Baumgartner, I; Bosiers, M; Brodmann, M; Micari, A; Scheinert, D; Shishehbor, MH; Vermassen, FEG; Wang, H; Zeller, T | 1 |
| Commeau, P; Desgranges, P; Ducasse, E; Feugier, P; Gouëffic, Y; Guyomarc'h, B; Hoffmann, CT; Kaladji, A; Leclere, B; Lermusiaux, P; Maurel, B; Pernès, JM; Rosset, E; Salomon du Mont, L; Sauguet, A | 1 |
| Amaravadi, RK; Bahary, N; Bartlett, DL; Boone, BA; Espina, V; Hogg, ME; Lee, KK; Liotta, L; Lotze, MT; Marsh, JW; Miller-Ocuin, JL; Murthy, P; Normolle, DP; Seiser, N; Singhi, AD; Tang, D; Tsung, A; Zeh, HJ; Zureikat, AH | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Han, J; Meng, Y; Song, Y; Sun, L; Wang, W; Yin, H; Zhang, J; Zhang, X; Zhao, W; Zheng, M | 1 |
| Chen, X; Liu, Y; Singh, N; Wang, J; Zhang, WW; Zhao, J | 1 |
| Leng, R; Li, CM; Ren, HL; Wang, Q; Zhang, WD; Zhu, RM | 1 |
| Ansel, GM; Dake, MD; Fanelli, F; Fu, W; Iida, O; Jiang, X; Lottes, AE; O'Leary, EE; Reichert, H; Schermerhorn, M; Zeller, T; Zen, K | 1 |
| Ahlström, H; Botling, J; Dahlstrand, H; Koliadi, A; Öberg, K; Tholander, B; Ullenhag, GJ; Von Heideman, A | 1 |
| Bouchard, L; Caty, V; Cournoyer, S; Ethier, J; Francoeur, M; Gilbert, P; Giroux, MF; Lespérance, J; Oliva, VL; Ouellet, G; Perreault, P; Soulez, G; Therasse, E | 1 |
| Chong, TT; Karnabatidis, D; Kitrou, PM; Ko, PJ; Lin, CH; Pegis, JD; Pietura, R; Ponce, P | 1 |
| Alós, J; Arjumand, J; Härtel, D; Hohl, C; Korosoglou, G; Langhoff, R; Martínez, E; Raut, W; Reimer, P; Riazi, H; Romani, S; Schmidt, A; Waliszewski, M; Yahya, SA | 1 |
| Bajardi, G; Dinoto, E; Ferlito, F; Mirabella, D; Pakeliani, D; Pecoraro, F | 1 |
| Bijlstra, OD; de Borst, GJ; de Vries, JPM; Knippenberg, B; Mali, WPTM; Martens, JM; Spreen, MI; Statius van Eps, RG; van Dijk, LC; van Overhagen, H; Vonken, EPA; Vos, JA; Wever, JJ | 1 |
| Cheng, Y; Conditt, GB; Gasior, P; Granada, JF; Kaluza, GL; McGregor, J; Valencia, AF | 1 |
| Bausback, Y; Del Giudice, C; Diaz-Cartelle, J; Geist, V; Lichtenberg, M; Marx, C; Sauguet, A; Scheinert, D; Schult, I; Sievert, H; Ströbel, A; Willfort-Ehringer, A | 1 |
| Broggini, M; Damia, G; Guffanti, F; Ricci, F | 1 |
| Hlinomaz, O; Kukla, P; Pleva, L; Zapletalova, J | 1 |
| Baber, U; Camenzind, E; Chieffo, A; Dangas, GD; Faggioni, M; Farhan, S; Galatius, S; Giustino, G; Harari, R; Itchhaporia, D; Jeger, RV; Kandzari, D; Kastrati, A; Kim, HS; Kimura, T; Leon, MB; Mehran, R; Mehta, L; Morice, MC; Sartori, S; Serruys, PW; Sharma, M; Smits, PC; Sorrentino, S; Stefanini, GG; Steg, PG; Stone, GW; Valgimigli, M; Von Birgelen, C; Weisz, G; Wijns, W; Windecker, S | 1 |
| Bunch, F; Carr, J; Kassab, E; Walker, C | 1 |
| Cassese, S; Dewitz, K; Fusaro, M; Groha, P; Hadamitzky, M; Ibrahim, T; Kasel, AM; Kastrati, A; Kufner, S; Laugwitz, KL; Ott, I; Schunkert, H; Steppich, B; Voll, F; Wittmann, T | 1 |
| Gemma, A; Hirose, T; Kobayashi, Y; Kubota, K; Miya, T; Shimizu, M; Takahashi, A | 1 |
| Amann-Vesti, B; Blessing, E; Jaff, MR; Krzanowski, M; Langhoff, R; Peeters, P; Rocha-Singh, KJ; Scheinert, D; Sixt, S; Tepe, G; Torsello, G; Zeller, T | 1 |
| Brodmann, M; Jaff, MR; Keirse, K; Li, P; Scheinert, D; Schmahl, R; Spak, L; Zeller, T | 1 |
| Chisci, E; Frosini, P; Guidotti, A; Michelagnoli, S; Romano, E; Troisi, N | 1 |
| Fujita, J; Furukawa, H; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kimura, Y; Makari, Y; Mikami, J; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
| Hara, H; Hasegawa, Y; Homma, A; Kiyota, N; Minato, K; Muro, K; Onoe, T; Saijo, K; Suzuki, M; Taguchi, J; Tahara, M; Takahashi, S; Ueda, S; Yamanaka, T; Yane, K; Yokota, T | 1 |
| Claes, K; Cornelissen, S; Fourneau, I; Henroteaux, D; Laenen, A; Maleux, G; Vander Mijnsbrugge, W; Verbeeck, N | 1 |
| Alston, M; Ansel, GM; Collins, C; Falls, A; Kolluri, R; Mohir-Sadaai, S; Patil, N; Phillips, JA; Reid, B; Troyan, M; Whipp, A | 1 |
| Azuma, K; Hoshino, T; Imamura, Y; Ishii, H; Kinoshita, T; Matsuo, N; Naito, Y; Tokito, T; Yamada, K | 1 |
| Del Giudice, C; Diaz-Cartelle, J; Geist, V; Lichtenberg, M; Marx, C; Sauguet, A; Scheinert, D; Schult, I; Sievert, H; Steiner, S; Ströbel, A; Willfort-Ehringer, A | 1 |
| Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ | 1 |
| Brodmann, M; Frost, M; Keirse, K; Micari, A; Peeters, P; Tepe, G; Wang, H; Zeller, T | 1 |
| Argyriou, A; Beropoulis, E; Bisdas, T; Stavroulakis, K; Torsello, G | 1 |
| Bossi, I; Caria, MP; Colombo, P; D'Anna, M; De Marco, F; Klugmann, S; Oliva, F; Oreglia, J; Piccalò, G; Piccaluga, E; Soriano, F; Vaccaro, V | 1 |
| Higashi, T; Mase, K; Mizutani, M; Moriya, T; Onodera, Y; Ozawa, K; Takagi, S; Takeshita, A; Usuba, O; Yokoyama, M | 1 |
| Hamaguchi, Y; Kitano, T; Maeda, S; Matsumoto, I; Mizumaki, K; Oishi, K; Saito, D; Takehara, K; Yoshida, S | 1 |
| Allen, R; Burgess, D; Cassorla, G; Farlow, D; Gruenewald, S; Hitos, K; Huber, D; Kairaitis, L; Larcos, G; Leo, C; Niknam, F; Swinnen, JJ; Villalba, LM | 1 |
| Ishimoto, H; Mukae, H; Noguchi, S; Shimabukuro, I; Tanaka, F; Torii, R; Uyama, K; Yatera, K; Yoshii, C | 1 |
| Brodmann, M; Granada, JF; Jaff, MR; Krüger, K; Meyer, DR; Reimer, P; Schroeder, H; Werner, M | 1 |
| Blagden, SP; DeSilvio, M; Frangou, E; Gabra, H; Goh, JC; Gopalakrishna, P; Hall, M; Hamilton, AL; Lisyanskaya, AS; Meniawy, TM; Michael, A; Mileshkin, L; Stronach, EA; Wong, S | 1 |
| Honton, B; Philippart, R; Sauguet, A | 1 |
| Yildiz, I | 1 |
| Chervenkoff, V; Esposito, G; Gerardi, D; Giugliano, G; Goverde, P; Kotasov, D; Magliulo, F; Stabile, E; Taeymans, K; Trimarco, B; Zhelev, D | 1 |
| Jaff, MR; Keirse, K; Li, P; Micari, A; Scheinert, D; Schmahl, R; Tepe, G; Zeller, T | 1 |
| Alsop, K; Beach, J; Bild, A; Bowtell, DDL; Brady, SL; Christie, EL; Copeland, A; deFazio, A; Fereday, S; Hendley, J; Lamb, G; Pandey, A; Pattnaik, S; Rashoo, N; Thorne, H | 1 |
| Albain, KS; Baltay, M; Barry, WT; Burstein, HJ; Carey, LA; Dang, CT; Dillon, DA; Ellis, MJ; Fuhrman, K; Guo, H; Hudis, CA; Krop, IE; Marcom, PK; Moy, B; Overmoyer, B; Partridge, AH; Pernas, S; Ritterhouse, L; Rugo, HS; Schneider, BP; Shapira, I; Shen, F; Tolaney, SM; Winer, EP; Wolff, AC; Yardley, DA | 1 |
| Adachi, A; Bolstad, F; Fujimura, N; Ichihashi, S; Iwakoshi, S; Kichikawa, K; Kyuragi, R; Nagatomi, S; Obayashi, K; Saeki, K; Shibata, T; Yamamoto, H | 1 |
| Okamura, K; Shirai, K; Urata, H; Yamamoto, T | 1 |
| Wang, L; Xia, ZJ | 1 |
| Beschorner, U; Brechtel, K; Dake, MD; Kultgen, PL; Noory, E; Rastan, A; Tepe, G; Zeller, T | 1 |
| Biamino, G; Castriota, F; Cioppa, A; Cremonesi, A; Grattoni, C; Liso, A; Marchese, A; Micari, A; Pantaleo, P; Rubino, P; Vadalà, G | 2 |
| de Boer, SW; de Vries, JP; Elgersma, O; Fioole, B; Heyligers, JM; Karimi, A; Lohle, PN; Nolthenius, RP; van den Heuvel, DA; Vos, JA; Vroegindeweij, D | 1 |
| Byrne, RA; Cassese, S; Fusaro, M | 1 |
| Kawamura, M; Kyoda, S; Nakano, S; Tabei, I; Takeyama, H; Yoshida, K | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Arellano, M; Bumpers, K; Flowers, CR; Heffner, LT; Hutcherson, D; Kaufman, J; King, N; Langston, A; Lechowicz, MJ; Lonial, S; Nooka, A; Shenoy, PJ; Sinha, R; Waller, EK | 1 |
| Kamura, T; Muto, M; Nishio, S; Ota, S; Sonoda, G; Takemoto, S; Ushijima, K | 1 |
| Angioli, P; Bellandi, G; Bolognese, L; Ducci, K; Falsini, G; Grotti, S; Liistro, F; Porto, I; Ricci, L; Turini, F; Ventoruzzo, G | 2 |
| Beschorner, U; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
| Aono, T; Deguchi, K; Deguchi, T; Endo, S; Fujitani, K; Fukui, A; Fushimi, H; Higashi, S; Iwase, K; Kawada, J; Matsuda, C; Nishikawa, K; Noguchi, Y; Nomura, M; Okumura, Y; Takagi, M; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Ishikawa, T; Mizuyama, Y; Nakagawa, H; Ohno, Y; Shinto, O; Takashima, T; Tamura, T | 1 |
| Nagahara, M; Nakagawa, T; Sato, T; Sato, Y; Sugihara, K | 1 |
| Enomoto, T; Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N; Watanabe, M | 1 |
| Alvero, AB; Azodi, M; Craveiro, V; Gill, SK; Griffin, B; Holmberg, JC; Joo, WD; Mor, G; Pizzonia, J; Rutherford, T; Silasi, DA; Sumi, NJ; Yang-Hartwich, Y | 1 |
| Kashihara, H; Murata, T; Shimizu, Y; Taga, R; Tsuji, K; Yamada, C; Yonezawa, M; Yoshino, H | 1 |
| Goto, Y; Kato, H; Matano, Y; Nishino, A; Tsukayama, S; Yoshimitsu, M | 1 |
| Alexandre, J; Emile, G; Gataa, I; Goldwasser, F; Loriot, MA | 1 |
| Fang, HC; Lai, CC; Liu, CP; Mar, GY; Tseng, CJ | 1 |
| Chen, F; Chen, S; Fu, G; Gao, R; Ge, J; Han, Y; Li, Z; Liu, B; Wang, J; Xu, B; Yang, Y; Zhao, Y | 1 |
| Alfonso, F; Bañuelos, C; Gonzalo, N; Jimenez-Quevedo, P; Medina, M | 1 |
| Biamino, G; Cioppa, A; Cota, L; Esposito, G; Giugliano, G; Popusoi, G; Pucciarelli, A; Rubino, P; Salemme, L; Stabile, E; Tesorio, T; Trimarco, B; Virga, V | 1 |
| Karunanithy, N; Katsanos, K; Krokidis, M; Sabharwal, T; Spiliopoulos, S; Taylor, P | 1 |
| Becquemin, JP; Houbballah, R; Leopardi, M | 1 |
| Agrawal, AK; Mehta, PS; Reddy-Holdcraft, S | 1 |
| Dang, NH; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, FB; Loyer, E; McLaughlin, P; Nastoupil, L; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Westin, JR; Younes, A | 1 |
| Jonas, W; Li, X; Liu, Y; Nikolinakos, P; O'Regan, RM; Pippas, A; Srinivasiah, J; Torres, M; Zelnak, AB | 1 |
| Miller, A; Natarajan, P | 1 |
| Karnabatidis, D; Katsanos, K; Kitrou, PM; Siablis, D; Spiliopoulos, S | 1 |
| Abrignani, S; Altobelli, S; D'Onofrio, A; Da Ros, V; Del Giudice, C; Gandini, R; Sallustio, F; Simonetti, G; Stanzione, P; Vasili, E | 1 |
| Herten, M; Imm, B; Osada, N; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
| Amano, S; Enomoto, K; Hara, Y; Makishima, M; Nagashima, S; Sakurai, K; Suzuki, S | 1 |
| Aguilar-Pérez, M; Arnold, G; Bäzner, H; Fischer, S; Henkes, H; Kurre, W; Schmid, E | 1 |
| Fujihara, M; Higashimori, A; Nakamura, M; Utsunomiya, M; Yokoi, Y | 1 |
| Chaillou, P; Costargent, A; Fairier, D; Gestin, S; Gouëffic, Y; Guyomarch, B; Kaladji, A; Montagne, C; Patra, P; Riche, VP; Vent, PA | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Aloysius, H; Hu, L | 1 |
| Bessette, P; Brown, C; Cretin, J; Dell'Anna, T; du Bois, A; Ferrero, A; Gladieff, L; Havsteen, H; Lorusso, D; Mahner, S; Meier, W; Pujade-Lauraine, E; Vasey, P; Vergote, I; Zeimet, AG | 1 |
| Fujita, S; Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kumagai, T; Mori, M; Morita, S; Negoro, S; Nishimura, T; Satouchi, M; Shimada, T; Sunadome, H; Tachihara, M; Urata, Y; Yoneda, T | 1 |
| Fujii, K; Kan, S; Kawashima, M; Kiso, M; Takeyama, O; Tanaka, M | 1 |
| Fuku, Y; Goto, T; Habara, S; Hasegawa, D; Kadota, K; Katoh, H; Kubo, S; Mitsudo, K; Otsuru, S; Tada, T; Tanaka, H | 1 |
| Albrecht, T; Brechtel, K; Claussen, CD; Scheller, B; Schnorr, B; Speck, U; Tepe, G; Zeller, T | 1 |
| Beckebaum, S; Cicinnati, VR; Hüsing, A; Kabar, I; Reinecke, H; Schmidt, HH; Wilms, C | 1 |
| Duda, S; Lux, B; Martorana, M; Meyer, DR; Ruecker, F; Schroeder, H | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S | 1 |
| Amano, H; Fuku, Y; Goto, T; Habara, S; Hasegawa, D; Hayakawa, Y; Hosogi, S; Hyoudou, Y; Ichinohe, T; Izawa, Y; Kadota, K; Kanazawa, T; Katoh, H; Kubo, S; Mitsudo, K; Miyake, K; Ohya, M; Otsuru, S; Sabbah, MM; Tada, T; Tanaka, H | 1 |
| Buecker, A; Fries, P; Massmann, A; Minko, P; Obst-Gleditsch, K; Shayesteh-Kheslat, R | 1 |
| Glogar, D; Gyöngyösi, M; Hemetsberger, R; Huber, K; Maurer, G; Park, J; Pavo, IJ; Pavo, N; Petnehazy, O; Petrasi, Z; Posa, A; Rajamannan, NM; Spargias, K; von Strandmann, RP | 1 |
| Biondi-Zoccai, G; Cancelli, I; Divis, P; Frati, G; Frigatti, P; Gasparini, D; Gavrilovic, V; Marullo, AG; Piccoli, G; Radici, V | 1 |
| Fujii, K; Iwai, N; Kataoka, K; Masuzawa, A; Matsumoto, N; Morita, Y; Takada, R; Takami, S; Takaya, H; Tanaka, N; Wakabayashi, N; Yoriki, H | 1 |
| Amiji, MM; Duan, Z; Feng, Y; Foster, R; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Yang, X | 1 |
| Hirano, K; Ishimori, H; Ito, Y; Mori, S; Muramatsu, T; Nakano, M; Tsukahara, R | 1 |
| Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y | 1 |
| Pityk, AI | 1 |
| Donas, KP; Herten, M; Osada, N; Stahlhoff, S; Torsello, G | 1 |
| Alfonso, F; Ansel, G; Cortese, B; Garcia, L; Granada, JF; Scheinert, D; Scheller, B; Schneider, PA; Stabile, E; Tepe, G; Zeller, T | 1 |
| Iida, O; Kawasaki, D; Nakano, M; Nanto, S; Soga, Y; Takahara, M; Uematsu, M; Yamauchi, Y; Yokoi, H; Zen, K | 1 |
| Amano, H; Fuku, Y; Goto, T; Habara, S; Hasegawa, D; Hyodo, Y; Izawa, Y; Kadota, K; Kubo, S; Mitsudo, K; Ohya, M; Otsuru, S; Shimada, T; Tada, T; Tanaka, H | 1 |
| Hase, K; Hasegawa, S; Moriya, T; Sakaguchi, N; Tsuda, H; Yamagishi, Y; Yamamoto, J; Yamazaki, T | 1 |
| Amoroso, G; Herrman, JP; Patterson, MS; Slagboom, T; van der Schaaf, RJ; Vink, MA; Vos, NS | 1 |
| Banno, E; Kanno, N; Kino, S; Nagai, Y; Nishino, A; Tahara, H; Yasuda, M | 1 |
| Kayser, G; Klement, GL; Rössler, J; Saueressig, U; von Winterfeld, M | 1 |
| Beschorner, U; Bosiers, M; Brodmann, M; Deloose, K; Peeters, P; Pilger, E; Rastan, A; Scheinert, D; Schulte, KL; Zeller, T | 1 |
| Banning-Eichenseer, U; Bausback, Y; Scheinert, D; Scheinert, S; Schmidt, A; Steiner, S; Ulrich, M; Werner, M | 1 |
| Dirksen, MT; Kiemeneij, F; Laarman, G; Patterson, MS; Slagboom, T; Suttorp, MJ; Vink, MA; Vos, NS | 1 |
| Ebisui, C; Fukuchi, N; Kinuta, M; Murata, K; Nushijima, Y; Okada, K; Okamura, S; Yanagisawa, T; Yokouchi, H | 1 |
| Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Paraskevopoulos, I; Spiliopoulos, S | 1 |
| Dansey, K; Shames, M; Wooster, M | 1 |
| Ansel, GM; Dake, MD; Jaff, MR; Machan, LS; O'Leary, EE; Ohki, T; Ragheb, AO; Saxon, RR; Smouse, HB; Snyder, SA; Zeller, T | 1 |
| Fitzgerald, PJ; Fujii, K; Fukunaga, M; Honda, Y; Horimatsu, T; Imanaka, T; Ishihara, M; Kawasaki, D; Kimura, T; Masuyama, T; Miki, K; Nishimura, M; Okada, K; Saita, T; Shibuya, M; Sumiyoshi, A; Tamaru, H | 1 |
| Andorfer, P; Heinzel, A; Heuwieser, A; Lukas, A; Mayer, B; Perco, P | 1 |
| Banning-Eichenseer, U; Bausback, Y; Bräunlich, S; Scheinert, D; Schmidt, A; Steiner, S; Ulrich, M | 1 |
| Ketelsen, D; Müller-Hülsbeck, S; Ricke, J; Rosenfield, K; Scheinert, D; Schmidt, A; Schröder, H; Sixt, S; Steiner, S; Weiss, N; Zeller, T | 1 |
| Goodarzi, H; Nguyen, A; Tavazoie, SF; Yoshida, M | 1 |
| Cui, S; Hu, X; Liao, N; Liu, D; Luo, R; Sun, Q; Wang, X; Xu, B; Yu, S; Zhang, Q; Zheng, H | 1 |
| Funovics, M; Gschwandtner, M; Javor, D; Kinstner, CM; Koppensteiner, R; Lammer, J; Loewe, C; Matzek, W; Ristl, R; Schoder, M; Willfort-Ehringer, A; Wolf, F | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Mo, H; Wang, J; Wang, X; Xu, B; Yin, Y; Yuan, P; Zhang, B; Zhang, P; Zheng, S | 1 |
| Kret, MR; Lee, JT; Tran, K; Ullery, BW | 1 |
| Hirano, K; Iida, O; Soga, Y; Takahara, M; Uematsu, M; Yamauchi, Y; Yokoi, H; Zen, K | 1 |
| Chesi, M; Dueck, AC; Fonseca, R; Ginos, BF; Jain, T; Keith Stewart, A; Kosiorek, HE; Leif Bergsagel, P; Mayo, A; Mikhael, J; Reeder, CB | 1 |
| Bi, W; Fu, W; Guo, P; Guo, W; Jia, X; Wang, F; Wang, S; Wu, D; Zhang, J; Zhao, Y; Zhuang, B | 1 |
| Aerden, D; Debing, E; Gallala, S; Vanhulle, A; von Kemp, K | 1 |
| Aschenbach, R; Blessing, E; Brechtel, K; Lehmann, T; Lichtenberg, M; Riambau, V; Scheinert, D; Sixt, S; Teichgräber, U; Thieme, M; Treitl, M; Vogel, B; von Flotow, P; Werk, M; Wienke, A; Zeller, T | 1 |
| Bague, N; Cardon, JM; Chatelard, P; Commeau, P; Garbé, JF; Gouëffic, Y; Guyomarch, B; Julia, P; Penillon, S; Pernès, JM; Planché, O; Sauguet, A | 1 |
| Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T | 1 |
| Fujii, K; Fujino, A; Hao, H; Hirota, S; Imanaka, T; Ishihara, M; Kawakami, R; Saita, T; Tsuchida, YA | 1 |
| Iida, O; Kawasaki, D; Matoba, S; Nanto, S; Soga, Y; Takahara, M; Yokoi, H; Zen, K | 1 |
| Akduman, EI; Altinbas, NK; Bilici, M; Oz, EB; Oz, II; Serifoglu, I | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Karnabatidis, D; Kitrou, P | 1 |
| Hennebry, TA; Latif, F | 1 |
| Boettcher, HF; Dietz, U; Hamm, B; Hosten, N; Langner, S; Reinkensmeier, B; Ricke, J; Speck, U; Tepe, G; Werk, M | 1 |
| Fujii, T; Ikejiri, K; Koike, K; Sasada, S; Takahashi, H; Yokoyama, G | 1 |
| Douis, H; Lipkin, G; Riley, P; Shabir, S | 1 |
| Briguori, C; Taranto, D; Visconti, G | 1 |
| Kadota, J; Miyamoto, K; Tamura, A; Watanabe, T | 1 |
| Airaksinen, KE; Karjalainen, PP; Kervinen, K; Mäkikallio, T; Niemelä, M; Nyman, K; Pietili, M; Sia, J; Tuomainen, P; Ylitalo, A | 1 |
| Park, SJ | 1 |
| Angiolillo, DJ; Bass, TA; Capranzano, P; Di Salvo, M; Galassi, AR; Guzman, LA; La Manna, A; Tamburino, C; Ussia, G | 1 |
| Blagden, S; Brooks, A; Gabra, H; Graham, J; Mitchell, H; Sharma, R | 1 |
| Jones, HR; Srinivasan, J | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Brodie, BR; Dangas, G; Dudek, D; Gersh, BJ; Guagliumi, G; Kellock, A; Lansky, AJ; Mehran, R; Möckel, M; Ochala, A; Parise, H; Peruga, JZ; Pocock, SJ; Stone, GW; Witzenbichler, B; Wong, SC | 1 |
| Capasso, M; De Luca, G; Di Lorenzo, E; Lanzillo, T; Manganelli, F; Mariello, C; Pagliuca, MR; Rosato, G; Sauro, R; Siano, F; Stanco, G; Varricchio, A | 1 |
| Aharonian, VJ; Brar, SK; Brar, SS; Dangas, G; Gray, WA; Leon, MB; Moses, JW | 1 |
| Banerjee, S; Berger, P; Bissett, JK; Brilakis, ES; de Lemos, JA; Fasseas, P; Haagen, D; Holper, EM; Iturbe, JM; Kar, B; Karyofillis, P; Lichtenwalter, C; Obel, O; Roesle, M; Rossen, J; Sachdeva, R; Saeed, B; Shunk, K; Voudris, VV | 1 |
| Amant, F; Berteloot, P; Leunen, K; Neven, P; Vandenput, I; Vergote, I | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Kitagawa, R; Konishi, I; Saito, I; Shibata, T; Yoshikawa, H | 1 |
| Asada, T; Chijiiwa, K; Eto, TA; Futami, S; Hidaka, H; Imada, S; Shibata, N; Shimayama, T; Takaya, T; Tanaka, S | 1 |
| Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
| Ackermann, H; Boxberger, M; Buerke, M; Cremers, B; Degenhardt, R; Figulla, HR; Hardt, S; Heuer, H; Kleber, FX; Leschke, M; Scheller, B; Unverdorben, M; Vallbracht, C | 1 |
| Belani, CP; Evans, T; Foster, J; Gooding, W; Ramalingam, SS; Sulecki, M | 1 |
| Cassese, S; Chiariello, M; D'Andrea, C; De Rosa, R; Galasso, G; Piccolo, R; Piscione, F | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Kang, HJ; Kim, HS; Kim, SY; Koo, BK; Lee, SP; Park, KW; Shin, DH; Suh, JW; Yeon, TJ | 1 |
| Beqiri, A; Berti, S; Gianetti, J; Palmieri, C; Paradossi, U; Ravani, M; Rizza, A; Trianni, G; Vaghetti, M | 1 |
| Budoff, MJ; Gupta, M | 1 |
| Betof, A; Blackwell, K; Craciunescu, O; Dewhirst, MW; Jones, E; Kim, DW; Lan, L; Liotcheva, V; McCall, L; Stauffer, P; Vujaskovic, Z | 1 |
| Saito, T; Sasaki, H; Tokunaga, Y | 1 |
| Bae, JH; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Cho, Y; Choi, DJ; Chung, WY; Hong, TJ; Hur, SH; Jang, YS; Jeong, KT; Jeong, MH; Kim, DI; Kim, HS; Kim, MJ; Kim, YJ; Lee, MY; Oh, SK; Park, KS; Park, KW; Park, SK; Rha, SW; Seo, WW; Seong, IW; Yang, HM; Yoon, JH | 1 |
| Aavall-Lundqvist, E; Brown, C; du Bois, A; Ferrero, A; Gebski, V; Heywood, M; Jackisch, C; Joly, F; Kristensen, G; Le Fur, N; Lortholary, A; Pignata, S; Pujade-Lauraine, E; Sehouli, J; Vasey, PA; Vergote, I; Volgger, B; Wagner, U | 1 |
| Eller, J; Kahán, Z; Kelemen, G; Ormándi, K; Thurzó, L; Uhercsák, G | 1 |
| Fujikuni, N; Hashimoto, M; Iwako, H; Kuranishi, F; Kuroda, Y; Moriyuki, T; Niitsu, H | 1 |
| Borgato, L; Donach, ME; Furini, L; Lombardi, G; Nicoletto, MO; Palma, MD; Zustovich, F | 1 |
| Arase, K; Iizaka, M; Inoue, K; Kuriwaki, K; Sueta, A; Yamamoto, Y | 1 |
| Iizawa, H; Okada, T; Sakurai, N | 1 |
| Carrillo, P; Cordero, A; Frutos, A; López-Palop, R | 1 |
| Gomes, M; Groffsky, JL; Leville, CD; Long, TD; McMillan, WD; Schultz, SR | 1 |
| Kezic, I; Milović-Kovačević, M; Popov, I; Radošević-Jelić, L; Stamatovic, L | 1 |
| Chung, DH; Heo, DS; Jang, B; Jeon, YK; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Koh, Y; Lee, SH | 1 |
| Charnigo, R; Moliterno, DJ; Ziada, KM | 1 |
| Dirksen, MT; Kiemeneij, F; Laarman, GJ; Patterson, MS; Slagboom, T; Suttorp, MJ; Tijssen, JG; van Etten, J; Vink, MA | 1 |
| Bensimhon, A; Brodie, B; Cooper, M; Fleishman, N; Hansen, C; Kissling, G; McAlhany, C; Milks, S; Pokharel, Y; Stuckey, T | 1 |
| González Martín, A | 1 |
| Danno, K; Imaoka, S; Imasato, M; Kanoh, T; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Yano, H | 1 |
| Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA | 1 |
| Abdel-karim, AR; Addo, T; Banerjee, S; Berger, PB; Bissett, JK; Brilakis, ES; de Lemos, JA; Fasseas, P; Haagen, D; Kar, B; Karyofillis, P; Lichtenwalter, C; Michael, TT; Obel, O; Papayannis, A; Rangan, BV; Roesle, M; Rossen, J; Sachdeva, R; Saeed, B; Voudris, VV | 1 |
| Baskin, DE; Garg, SJ | 1 |
| Dirksen, MT; Ijsselmuiden, AJ; Kiemeneij, F; Laarman, GJ; Patterson, MS; Slagboom, T; Suttorp, MJ; Tijssen, JG; van Geloven, N; Vink, MA | 1 |
| Bacon, M; Brown, C; Donadello, N; Friedlander, M; Gebski, V; Gurney, H; Lee, CK; Lord, S; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, E; Reed, N; Simes, RJ; Sorio, R; Tulunay, G | 1 |
| Krause, U; Müller, MJ; Paul, T; Schneider, HE | 1 |
| Brown, C; Delva, R; Donadello, N; Friedlander, M; Gebski, VJ; Georgoulopoulos, A; Lee, CK; Lord, SJ; Mirza, MR; Pignata, S; Pujade-Lauraine, E; Sauthier, P; Schmalfeldt, B; Simes, RJ; Vergote, I | 1 |
| Aghajanian, CA; Berlin, S; Hensley, ML; Iasonos, A; Jia, X; Kravetz, S; Pereira, L; Sabbatini, P; Tew, W; Whalen, C; Zarwan, C | 1 |
| Brown, C; De Rauglaudre, G; Elit, L; Ferrero, A; Gladieff, L; Helland, H; Lorusso, D; Mahner, S; Pujade-Lauraine, E; Reed, N; Reinthaller, A; Siena, S; Vasey, P | 1 |
| Bosiers, M; Dake, MD; Fanelli, F; Kavteladze, Z; Lottes, AE; Ragheb, AO; Ruhlmann, C; Scheinert, D; Tepe, G; Tessarek, J; Zeller, T | 1 |
| Endo, S; Endo, T; Hasegawa, T; Hironaka, M; Nakano, T; Nakayama, M; Sugiyama, Y | 1 |
| Biamino, G; Castriota, F; Cioppa, A; Cremonesi, A; Grattoni, C; Marchese, A; Micari, A; Pantaleo, P; Rubino, P; Stabile, E; Vadalà, G | 1 |
| Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM | 1 |
| Egawa-Takata, T; Enomoto, T; Fujita, M; Fujiwara, K; Kamiura, S; Kimura, T; Miyatake, T; Ohta, Y; Ueda, Y; Yoshino, K | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Fujiwara, T; Kagawa, S; Kanaya, N; Kunitomi, A; Ogawa, N; Uno, F | 1 |
| Alexandre, J; Brown, C; Chalchal, H; Coeffic, D; Ferrero, A; Fitzharris, B; Mäenpää, J; Pfisterer, J; Pisano, C; Pujade-Lauraine, E; Raban, N; Vergote, I; Volgger, B | 1 |
| Airaksinen, KE; Karjalainen, PP; Kervinen, K; Nammas, W; Niemelä, M; Nyman, K; Pietilä, M; Sia, J; Tuomainen, PO; Ylitalo, A | 1 |
| Chechi, T; Cortese, G; De Luca, G; Di Lorenzo, E; Díaz de la Llera, LS; Dirksen, MT; Kaiser, C; Kelbaek, H; Musto, C; Pasceri, V; Schalij, M; Spaulding, C; Spaziani, G; Stone, GW; Suryapranata, H; Thuesen, L; van der Hoeven, B; Vink, MA; Violini, R | 1 |
| Boere, IA; van der Burg, ME | 1 |
| Bonaventura, T; Brown, C; Fossati, R; Gebski, V; Heywood, M; Kaern, J; Largillier, R; Lauraine, EP; Marth, C; Piccirillo, MC; Vergote, I; Wagner, U | 1 |
| Minar, E; Schillinger, M | 1 |
| Borges, AC; Bräutigam, M; Clever, Y; Cremers, B; Dietz, U; Richter, W; Rutsch, W; Scheller, B; Speck, U | 1 |
| Alba, E; Jiménez, B; Llácer, C; Medina, L; Navarro, V; Pajares, BI; Quero, C; Rueda, A; Sáez, MI; Trigo, JM | 1 |
| Boatta, E; Cannavale, A; Cirelli, C; Corona, M; Fanelli, F; Lucatelli, P; Salvatori, FM; Wlderk, A | 1 |
| Jinta, E; Sakurai, T; Suzuma, T; Umemura, T; Yoshimura, G | 1 |
| Bellandi, G; Bolognese, L; Grotti, S; Liistro, F; Porto, I; Ventoruzzo, G; Vergallo, R | 1 |
| Bartorelli, AL; Fabbiocchi, F; Galli, S; Lualdi, A; Montorsi, P; Ravagnani, PM; Riva, G; Teruzzi, G; Trabattoni, D; Troiano, S | 1 |
| Abbott, JD; Faxon, D; Holper, E; Kelsey, S; Khandhar, S; Kip, KE; Kutcher, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Selzer, F; Smith, C; Toma, C; Vlachos, HA; Williams, DO | 1 |
| Kondo, J; Nagashima, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K | 1 |
| Brodie, BR; Bryniarski, L; Dudek, D; Dziewierz, A; Fahy, M; Kornowski, R; Lansky, AJ; Legutko, J; Mehran, R; Rakowski, T; Stone, GW; Witzenbichler, B | 1 |
| Logothetis, CJ | 1 |
| Antonopoulos, MJ; Gregoriou, A; Kosmas, C; Malamos, NA; Rokana, S; Stamataki, M; Tsavaris, NB; Vartholomeou, M | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Gershlick, A; Hogrefe, K; Javed, Q; Swanson, N | 1 |
| Krempien, R; Piroth, MD; Wannenmacher, M; Zierhut, D | 1 |
| Fausel, C; Motl, SE | 1 |
| Duda, SH; Haase, KK; Poerner, TC; Rundback, JH; Tepe, G; Wiesinger, B; Wiskirchen, J | 1 |
| Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F | 1 |
| Imazu, H; Matsubara, T; Nakamura, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I | 1 |
| Cho, MC; Kim, DW; Kim, MS; Kim, YG; Kwon, JS; Lee, GS; Youn, TJ | 1 |
| Machan, L | 1 |
| Burke, T; Cooper, J; Fontenesci, J; Greven, K; Underhill, K; Winter, K | 1 |
| Arampatzis, CA; de Feyter, PJ; Hoye, A; Lemos, PA; McFadden, E; Ong, AT; Serruys, PW; Sianos, G; van der Giessen, WJ; van Domburg, RT; van Mieghem, CA | 1 |
| Franke, A; Grube, E; Hanrath, P; Hoffmann, R; Kaiser, A; Kobella, S; Radke, PW; Schubert, D | 1 |
| Brown, R; Gifford, G; Kaye, SB; Paul, J; Vasey, PA | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Claussen, CD; Duda, SH; Kehlbach, R; Schart, N; Schöber, W; Tepe, G; Wersebe, A; Wiskirchen, J | 1 |
| Alden, M; Borghaei, H; Millenson, M; Padavic-Shaller, K; Rogatko, A; Schilder, R; Smith, MR; Wang, H | 1 |
| Herzog, TJ | 1 |
| Casas, F; Jeremic, B | 1 |
| Bergin, P; Caputo, R; Cox, DA; Ellis, SG; Greenberg, J; Hermiller, J; Koglin, JJ; Lasala, JM; Mann, JT; O'shaughnessy, C; Popma, JJ; Stone, GW; Turco, M | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Brown, AM; Bryant, J; Dakhil, SR; Davidson, NE; Fehrenbacher, L; Geyer, CE; Ingle, JN; Jenkins, RB; Kaufman, PA; Klein, PM; Kutteh, LA; Lingle, WL; Mamounas, EP; Martino, S; Paik, S; Perez, EA; Pisansky, TM; Romond, EH; Suman, VJ; Swain, SM; Tan-Chiu, E; Visscher, DW; Vogel, VG; Wolmark, N; Yothers, G | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Anderson, RA; Bainbridge, A; Curzen, NP; Dawkins, KD; Fath-Ordoubadi, F; Swallow, RA; Younas, S | 1 |
| Fayad, L; Goy, A; Hagemeister, FB; Loyer, E; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Younes, A | 1 |
| Gréen, H; Horvath, G; Peterson, C; Rosenberg, P; Söderkvist, P | 1 |
| Belle, SV; Bougnoux, P; Cottu, PH; Cvitkovic, E; Delva, R; Deplanque, G; Extra, JM; Lotz, JP; Petit, T; Viens, P; Yovine, A | 1 |
| Barteczko, Z; Buszman, P; Gruszka, A; Milewski, K; Peszek-Przybyła, E; Radwan, K; Szkróbka, I; Tendera, M; Zurakowski, A | 1 |
| Airoldi, F; Biondi-Zoccai, G; Briguori, C; Carlino, M; Chieffo, A; Colombo, A; Cosgrave, J; Iakovou, I; Michev, I; Montorfano, M; Rogacka, R; Sangiorgi, GM; Stankovic, G | 1 |
| Fischi, M; Kakkar, AK; Narins, CR | 1 |
| Beatrice, S; De Marzi, P; Fazio, F; Frigerio, L; Gentile, C; Mangili, G; Rabaiotti, E; Viganò, R | 1 |
| Al-Ali, F; Barrow, T; Gupta, R; Hammer, MD; Horowitz, MB; Jovin, TG; Thomas, AJ; Uchino, K; Vora, NA; Wechsler, LR | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Blindt, R; Hoffmann, R; Iofina, E; Kelm, M; Kühl, H; Langenberg, R | 1 |
| Arellano, M; Flowers, C; Heffner, LT; Hutcherson, D; Jo Lechowicz, M; Langston, A; Lonial, S; Waller, EK; Winton, E | 1 |
| Bae, SH; Baek, JH; Cho, GJ; Chung, HY; Chung, JS; Do, YR; Hyun, MS; Jang, JS; Kim, JG; Kwon, KY; Lee, KH; Lee, WS; Park, KU; Ryoo, HM; Sohn, CH; Sohn, SK; Song, HS; Yu, W | 1 |
| Diestelhorst, A; Dunst, J; Fornara, P; Kühn, R; Kuhnt, T; Müller, AC; Scholz, HJ; Zietman, AL | 1 |
| Daemen, J; de Jaegere, PP; García-García, HM; Kukreja, N; Serruys, PW; Sianos, G; Tanimoto, S; van de Sande, M; van Domburg, RT | 1 |
| de Vries, MR; Eefting, D; Jukema, JW; Pires, NM; Quax, PH | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G; Pristipino, C; Richichi, G; Speciale, G | 1 |
| Cary-Ten Have Dallinga, M; El Kouri, C; Lortholary, A; Morineau, N; Ramée, JF | 1 |
| Bookman, MA | 1 |
| de Belder, MA; Kunadian, B; Vijayalakshmi, K | 1 |
| Di Lorenzo, E; Dibra, A; Goy, JJ; Jüni, P; Kaiser, C; Kastrati, A; Lee, JH; Mehilli, J; Meier, B; Park, SJ; Pfisterer, ME; Schömig, A; Suárez de Lezo, J; Windecker, S; Wu, J | 1 |
| Kereiakes, DJ | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Lair, BS; Martenson, JA; McLeod, HL; Moore, DF; Nichols, F; Tschetter, LK | 1 |
| Choi, BS; Robins, HI | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Bui, V; Chevreau, C; Delord, JP; Fizazi, K; Flechon, A; Geoffrois, L; Kerbrat, P; Lotz, JP; Theodore, C; Yataqhene, Y | 1 |
| Bae, SB; Cho, DY; Cho, IS; Han, CS; Kim, S; Lee, HJ; Lee, KT; Park, JC; Park, SY; Yun, HJ | 1 |
| Biondi-Zoccai, G; Moretti, C; Sheiban, I; Sillano, D | 1 |
| Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA | 1 |
| Chen, SL; Chen, YD; Kawajiri, K; Kwan, TW; Lee, M; Mintz, G; Patel, T; Tan, HC; Ye, F; Zhang, JJ | 1 |
| Barsness, GW; Bjarnason, H; Howe, PW; Hunt, C; Mathew, V; McKusick, MA; Misra, S; Pflueger, A; Textor, SC; Thatipelli, MR | 1 |
| Bates, S; Bryant, G; Chabner, BA; Cheson, BD; Fojo, A; Goldspiel, BR; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH | 1 |
| Adamo, DO; Bicher, A; Christian, M; Davis, P; Jacob, J; Kohn, E; Reed, E; Sarosy, G | 1 |
| Bishop, JF; Phillips, KA; Urch, M | 1 |
| Brown, WS; Cain, JM; Figge, DC; Greer, BE; Seewaldt, VL; Tamimi, HK | 1 |
| Hagemeister, F; McLaughlin, P; Melnyk, A; Moore, D; North, L; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Gelmon, K; Shenkier, T | 1 |
| Meehan, JL; Sporn, JR | 1 |
| Cabanillas, F; Callendar, D; Hagemeister, F; Mansfield, P; McLaughlin, P; Mesina, O; Moore, D; North, L; Rodriguez, MA; Romaguera, J; Sarris, AH; Swan, F; Younes, A | 1 |
| Abe, K; Fujii, H; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Sekine, I; Wakita, H | 1 |
| Ball, HG; Blessing, JA; Lentz, SS; Mutch, DG | 1 |
| Anteby, SO; Edelman, DZ; Peretz, T | 1 |
| Ayoub, JP; Bachier, C; Cabanillas, F; Hagemeister, F; Kurzrock, R; McLaughlin, P; North, L; Pate, O; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, T; Younes, A | 1 |
| Cabanillas, F; Farber, C; Hagemeister, FB; McLaughlin, PW; Myers, J; Pate, O; Portlock, C; Sarris, A; Younes, A | 1 |
| Arbuck, S; Dakhil, SR; Delmore, JE; Downey, G; Edwards, CL; Freedman, RS; Fueger, R; Gacrama, P; Greenberg, H; Kavanagh, JJ; Kudelka, AP; LoCoco, S; Loyer, E; Umbreit, J; Winn, R | 1 |
| Gian, VG; Johnson, TJ; Lynch, JW; Marsh, RW; Schuhmacher, C | 1 |
| Balcerzak, SP; Chapman, RA; Fisher, RI; Gagnet, S; LeBlanc, M; O'Rourke, TJ; Press, OW | 1 |
| Chase, EM; Dalton, WS; Dorr, R; Lam, KS; Miller, TP; Salmon, SE | 1 |
| Alvarez, R; Austin, JM; Barnes, MN; Kilgore, LC; Niwas, S; Partridge, EE; Robertson, MW; Roland, PY | 1 |
| Charnsangavej, C; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vasuratna, A; Verschraegen, CF; Wootipoom, V | 1 |
| Arbit, E; Lederman, G; Lombardi, E; Odaimi, M; Wertheim, S | 1 |
| Bergerat, JP; Deplanque, G; Duclos, B; Dufour, P; Eichler, F; Giron, C; Herbrecht, R; Kurtz, JE; Limacher, JM; Maloisel, F; Oberling, F | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, F; McLaughlin, P; Mesina, O; Preti, HA; Rodriguez, MA; Romaguera, J; Sarris, AH; Younes, A | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Borden, K; Duska, LR; Finkelstein, DM; Fuller, AF; Gallagher, J; Goodman, A; Makastorsis, T; Nikrui, N; Penson, R; Seiden, MV; Supko, JG | 1 |
| Burkes, R; Charpentier, D; Couture, F; Dulude, H; Glück, S; Goss, P; Kaizer, L; Klasa, R; Palmer, M; Stewart, AK; Tye, L | 1 |
| Anibali-Charpiat, MF; Calluaud, L; Fabre-Guillevin, E; Ravaud, A; Tchen, N | 1 |
| Blume, KG; Chao, NJ; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Alfonso, R; Casado, A; de Paz, L; Diaz-Rubio, E; Esteban, C; García-Conde, J; Garciía Carbonero, I; Insa, A; Lluch, A; Martín, M | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Blay, JY; Bouabdallah, K; Caillot, D; Casasnovas, RO; Dumontet, C; Gabarre, J; Gisselbrecht, C; Haioun, C; Lederlin, P; Morel, P; Quesnel, B; Richard, B; Stamatoullas, A | 1 |
| Axel, DI; Baumbach, A; Blattner, A; Heinle, H; Herdeg, C; Karsch, KR; Oberhoff, M; Schröder, S | 1 |
| Baumbach, A; Blattner, A; Herdeg, C; Karsch, KR; Küttner, A; Oberhoff, M; Schröder, S; Siegel-Axel, DI | 1 |
| Camidge, DR; Kunkler, IH | 1 |
| Bornstein, DA; Drachman, DE; Edelman, ER; Groothuis, AR; Kamath, KR; Nott, SH; Palasis, M; Rogers, C; Seifert, P; Yang, D | 1 |
| Kosmas, C; Koufos, C; Malamos, NA; Tsavaris, NB; Vadiaka, M | 1 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Mascolini, M | 1 |
| Dainer, PM; El Sobky, RA; Jillella, AP; Kallab, AM; Lesher, JL | 1 |
| Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
| Colombo, A; Liistro, F | 1 |
| Buekers, T; Buller, RE; Horowitz, JA; Karlan, BY; Kreienberg, R; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, M; Slamon, D | 1 |
| Buller, RE; Horowitz, JA; Karlan, B; Kreienberg, R; Mahavni, V; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, MS; Slamon, D | 1 |
| Gharacholou, SM; Krucoff, MW; Nilsson, KR; Sketch, MH | 1 |
| Claessens, P; Vanderheyden, M; Vankelecom, B; Willaert, W | 1 |
23 review(s) available for paclitaxel and Recrudescence
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A systematic review and meta-analysis of the risk of death and patency after application of paclitaxel-coated balloons in the hemodialysis access.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Directional atherectomy with antirestenotic therapy for the treatment of no-stenting zones.
Topics: Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Humans; Paclitaxel; Peripheral Arterial Disease; Recurrence; Risk Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Bayesian network meta-analysis of nitinol stents, covered stents, drug-eluting stents, and drug-coated balloons in the femoropopliteal artery.
Topics: Alloys; Amputation, Surgical; Angioplasty, Balloon; Bayes Theorem; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sirolimus; Stents; Treatment Outcome; Vascular Access Devices | 2014 |
Targeted prodrug approaches for hormone refractory prostate cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Therapy; Humans; Male; Nitric Oxide; Paclitaxel; Prodrugs; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Thapsigargin; Vinblastine | 2015 |
Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document.
Topics: Angioplasty, Balloon; Consensus; Drug Implants; Humans; Lower Extremity; Paclitaxel; Peripheral Vascular Diseases; Recurrence; Tubulin Modulators | 2016 |
Personalized Therapy for Generalized Lymphatic Anomaly/Gorham-Stout Disease With a Combination of Sunitinib and Taxol.
Topics: Administration, Metronomic; Adolescent; Child; Chronic Pain; Combined Modality Therapy; Dietary Fats; Drug Synergism; Drug Therapy, Combination; Fatal Outcome; Humans; Indoles; Lymphatic Abnormalities; Male; Osteolysis, Essential; Paclitaxel; Pelvic Bones; Pleural Effusion; Precision Medicine; Pyrroles; Radiography; Recurrence; Remission Induction; Respiration, Artificial; Respiratory Insufficiency; Sunitinib; Triglycerides | 2015 |
Systematic Review and Meta-analysis of Randomized Controlled Trials of Paclitaxel-Coated Balloon Angioplasty in the Femoropopliteal Arteries: Role of Paclitaxel Dose and Bioavailability.
Topics: Amputation, Surgical; Angioplasty, Balloon; Biological Availability; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Limb Salvage; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Drug eluting balloons for resistant arteriovenous dialysis access stenosis.
Topics: Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Graft Occlusion, Vascular; Humans; Models, Cardiovascular; Paclitaxel; Prosthesis Design; Recurrence; Renal Dialysis; Risk Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials.
Topics: Coronary Angiography; Death; Drug-Eluting Stents; Equipment Design; Humans; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Patient Selection; Randomized Controlled Trials as Topic; Recurrence; Risk; Sirolimus; Thrombosis; Treatment Outcome | 2009 |
Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Least-Squares Analysis; Metals; Middle Aged; Myocardial Infarction; Odds Ratio; Paclitaxel; Prosthesis Design; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Sirolimus; Stents; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
Topics: Angioplasty, Balloon, Coronary; Drug-Eluting Stents; Heart Conduction System; Humans; Incidence; Myocardial Infarction; Myocardial Revascularization; Odds Ratio; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sirolimus; Stents; Thrombosis; Time Factors | 2012 |
Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence | 2012 |
Innovative technologies for SFA occlusions: drug coated balloons in SFA lesions.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Cardiovascular Agents; Catheters; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Radiography; Recurrence; Treatment Outcome; Vascular Patency | 2012 |
Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Recurrence; Taxoids | 2002 |
Recurring chemotherapy-associated alopecia areata: case report and literature review.
Topics: Alopecia Areata; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Paclitaxel; Recurrence | 2003 |
Drug-eluting stents: potential applications for peripheral arterial occlusive disease.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Arterial Occlusive Diseases; Coronary Restenosis; Dexamethasone; Drug Delivery Systems; Humans; Immunosuppressive Agents; Paclitaxel; Prosthesis Design; Recurrence; Sirolimus; Stents; Vascular Patency | 2003 |
Drug eluting stents in the infrainguinal circulation.
Topics: Animals; Arterial Occlusive Diseases; Femoral Artery; Humans; Hyperplasia; Paclitaxel; Popliteal Artery; Radiography; Recurrence; Sirolimus; Stents; Tunica Intima; Vascular Patency | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction.
Topics: Drug Delivery Systems; Female; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Risk; Sirolimus; Stents; Survival Analysis; Thrombosis; Treatment Outcome; Tubulin Modulators | 2007 |
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Blood Vessel Prosthesis; Comorbidity; Coronary Artery Disease; Coronary Thrombosis; Drug Delivery Systems; Global Health; Humans; Immunosuppressive Agents; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Sirolimus; Stents; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2007 |
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neoplasms; Paclitaxel; Recurrence; Tamoxifen | 1996 |
124 trial(s) available for paclitaxel and Recrudescence
| Article | Year |
|---|---|
One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume
Topics: Adult; Coated Materials, Biocompatible; Dilatation; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Recurrence; Single-Blind Method; Treatment Outcome; Urethral Stricture | 2022 |
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence | 2023 |
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Recurrence; Small Cell Lung Carcinoma; Treatment Outcome | 2019 |
Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Postoperative Care; Recurrence; Risk Factors; Young Adult | 2019 |
ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Topics: Aged; Aged, 80 and over; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Brazil; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Length of Stay; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Europe; Female; Humans; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; France; Humans; Male; Metals; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Preoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Safety and Efficacy of Paclitaxel-Eluting Balloon Angioplasty for Dysfunctional Hemodialysis Access: A randomized trial Comparing with Angioplasty Alone.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Quebec; Recurrence; Renal Dialysis; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Critical Illness; Disease-Free Survival; Drug-Eluting Stents; Humans; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Netherlands; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Endovascular Procedures; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Topics: Aged; Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Calcification; Vascular Patency | 2017 |
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2018 |
Multicenter, Randomized Trial of Conventional Balloon Angioplasty versus Paclitaxel-Coated Balloon Angioplasty for the Treatment of Dysfunctioning Autologous Dialysis Fistulae.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Coated Materials, Biocompatible; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Recurrence; Treatment Outcome; Vascular Patency | 2018 |
12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Europe; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Multicentre, randomised, blinded, control trial of drug-eluting balloon vs Sham in recurrent native dialysis fistula stenoses.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; New South Wales; Paclitaxel; Recurrence; Renal Dialysis; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Access Devices; Vascular Patency | 2019 |
Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Europe; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Monitoring; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Recurrence; Thiophenes; Treatment Outcome | 2019 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The Chronic Total Occlusion Cohort in the IN.PACT Global Study.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Chronic Disease; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genotype; Humans; Lymph Nodes; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Poisson Distribution; Polymorphism, Single Nucleotide; Receptor, ErbB-2; Recurrence; Risk; Trastuzumab; Treatment Outcome | 2019 |
Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Topics: Aged; Alloys; Angioplasty, Balloon; Ankle Brachial Index; Canada; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Europe; Exercise Test; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Prosthesis Failure; Recurrence; Registries; Republic of Korea; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Randomized trial of Legflow(®) paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol fo
Topics: Alloys; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Equipment Failure; Femoral Artery; Hemodynamics; Humans; Hyperplasia; Limb Salvage; Neointima; Netherlands; Paclitaxel; Predictive Value of Tests; Prosthesis Design; Prosthesis Failure; Recurrence; Research Design; Resins, Plant; Single-Blind Method; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2013 |
Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Topics: Aged; Aged, 80 and over; Alloys; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Disease-Free Survival; Equipment Design; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Radiography; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study.
Topics: Aged; Angioplasty, Balloon; Aortic Dissection; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Double-Blind Method; Equipment Design; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Regional Blood Flow; Retreatment; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2013 |
Percutaneous angioplasty using a paclitaxel-coated balloon improves target lesion restenosis on inflow lesions of autogenous radiocephalic fistulas: a pilot study.
Topics: Aged; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Female; Graft Occlusion, Vascular; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Radial Artery; Radiography; Recurrence; Renal Dialysis; Time Factors; Treatment Outcome; Upper Extremity; Vascular Access Devices; Vascular Patency | 2014 |
A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; China; Coated Materials, Biocompatible; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Male; Middle Aged; Paclitaxel; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Topotecan; Treatment Outcome; Young Adult | 2014 |
High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Recurrence; Remission Induction; Survival Analysis; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angiography, Digital Subtraction; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug-Eluting Stents; Female; Greece; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Vascular Remodeling | 2014 |
Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Topics: Cardiovascular Agents; Clinical Protocols; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; France; Humans; Metals; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Research Design; Stents; Switzerland; Time Factors; Treatment Outcome | 2014 |
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Recurrence | 2015 |
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Risk Factors; Treatment Failure; Treatment Outcome | 2015 |
Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial.
Topics: Aged; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Radiography; Recurrence; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices | 2015 |
Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Disease-Free Survival; Female; Femoral Artery; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Radiography; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety | 2015 |
REVascularization with paclitaxEL-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarcTION-A randomized controlled trial: Rationale and design of the REVELATION trial.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiac Catheters; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Echocardiography; Fractional Flow Reserve, Myocardial; Humans; Netherlands; Paclitaxel; Prospective Studies; Prosthesis Design; Recurrence; Research Design; ST Elevation Myocardial Infarction; Time Factors; Treatment Outcome | 2016 |
Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjec
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Young Adult | 2015 |
Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention in Multivessel Coronary Disease Is Primarily Related to Stent Failure: Post-Hoc Analysis of the PASSION Trial.
Topics: Aged; Coronary Artery Disease; Drug-Eluting Stents; Equipment Failure; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Recurrence | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug-Eluting Stents; Equipment Failure; Female; Femoral Artery; Follow-Up Studies; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Popliteal Artery; Recurrence; Stents; Ticlopidine; Vascular Patency | 2016 |
German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Intermittent Claudication; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Austria; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Retreatment; Risk Factors; Single-Blind Method; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Phase II trial of nab-paclitaxel in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Albumins; Female; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence | 2016 |
Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
Topics: Aged; Amputation, Surgical; Angiography; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; China; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Paclitaxel-coated versus plain old balloon angioplasty for the treatment of infrainguinal arterial disease in diabetic patients: the Belgian diabetic IN.PACT Trial.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Belgium; Cardiovascular Agents; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2017 |
The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
Topics: Angiography, Digital Subtraction; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Clinical Protocols; Coated Materials, Biocompatible; Computed Tomography Angiography; Constriction, Pathologic; Exercise Tolerance; Female; Femoral Artery; Germany; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Quality of Life; Recovery of Function; Recurrence; Research Design; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency; Walking | 2016 |
Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial).
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Recurrence; Reoperation; Treatment Outcome | 2017 |
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Popliteal Artery; Propensity Score; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2017 |
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Disease-Free Survival; Drug Delivery Systems; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Paclitaxel; Peripheral Vascular Diseases; Pilot Projects; Popliteal Artery; Recurrence; Treatment Outcome | 2008 |
Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Recurrence; Risk Factors; Thrombosis; Titanium; Treatment Outcome | 2008 |
Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Recurrence; Retreatment; Risk; Stents; Sweden | 2009 |
The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Patient Selection; Platelet Aggregation Inhibitors; Prospective Studies; Prosthesis Design; Recurrence; Risk Assessment; Sirolimus; Stents; Thrombosis; Time Factors; Treatment Outcome | 2009 |
Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Artery Bypass; Coronary Restenosis; Drug-Eluting Stents; Graft Occlusion, Vascular; Greece; Humans; Metals; Myocardial Infarction; Paclitaxel; Prosthesis Design; Recurrence; Saphenous Vein; Single-Blind Method; Stents; Thrombosis; Time Factors; Treatment Outcome; United States | 2009 |
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Survival Analysis | 2009 |
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Protocols; Female; Follow-Up Studies; Humans; Japan; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Quality of Life; Recurrence; Research Design; Uterine Cervical Neoplasms | 2010 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Sirolimus; Ticlopidine | 2009 |
Treatment of small coronary arteries with a paclitaxel-coated balloon catheter.
Topics: Aged; Catheterization; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Recurrence; Stents; Treatment Outcome | 2010 |
Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recurrence; Retreatment; Small Cell Lung Carcinoma | 2010 |
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome | 2010 |
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence | 2010 |
5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Agents; Drug-Eluting Stents; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Metals; Myocardial Infarction; Netherlands; Paclitaxel; Proportional Hazards Models; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Single-Blind Method; Stents; Thrombosis; Time Factors; Treatment Outcome | 2011 |
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids | 2012 |
Lack of long-term clinical benefit of thrombus aspiration during primary percutaneous coronary intervention with paclitaxel-eluting stents or bare-metal stents: post-hoc analysis of the PASSION-trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Coronary Angiography; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Metals; Middle Aged; Myocardial Infarction; Netherlands; Odds Ratio; Paclitaxel; Propensity Score; Proportional Hazards Models; Prosthesis Design; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Suction; Thrombectomy; Time Factors; Treatment Outcome | 2012 |
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Recurrence | 2011 |
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Furans; Humans; Ketones; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Retreatment; Tubulin Modulators | 2012 |
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Recurrence; Treatment Outcome; Young Adult | 2012 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence; Treatment Outcome | 2012 |
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Humans; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence; Tomography, X-Ray Computed | 2012 |
Gender-based analysis of the 3-year outcome of bioactive stents versus paclitaxel-eluting stents in patients with acute myocardial infarction: an insight from the TITAX-AMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Death; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Paclitaxel; Recurrence; Retrospective Studies; Sex Characteristics; Stents; Titanium; Treatment Outcome | 2012 |
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence; Treatment Outcome | 2012 |
Intracoronary local paclitaxel delivery by X-ray contrast media for in-stent restenosis: a clinical pilot study to assess safety and tolerability.
Topics: Aged; Algorithms; Cardiac Catheterization; Cardiovascular Agents; Contrast Media; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Double-Blind Method; Female; Germany; Humans; Injections, Intra-Arterial; Iohexol; Male; Middle Aged; Paclitaxel; Pilot Projects; Recurrence; Stents; Treatment Outcome | 2012 |
Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Drug Carriers; Equipment Design; Female; Femoral Artery; Humans; Limb Salvage; Lower Extremity; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Rome; Severity of Illness Index; Stents; Thrombosis; Time Factors; Treatment Outcome; Vascular Access Devices | 2012 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Follow-Up Studies; Humans; Immunosuppressive Agents; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Registries; Retrospective Studies; Sirolimus; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States | 2013 |
Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial.
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Disease-Free Survival; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Recurrence; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2013 |
Isolated leptomeningeal carcinomatosis (carcinomatous meningitis) after taxane-induced major remission in patients with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Humans; Incidence; Meningeal Neoplasms; Meningitis; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Taxoids | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recurrence; Survival Analysis | 2004 |
Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy.
Topics: Coronary Angiography; Coronary Restenosis; Drug Implants; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Recurrence; Stents | 2004 |
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients.
Topics: Adaptor Proteins, Signal Transducing; Alleles; Carboplatin; Carrier Proteins; CpG Islands; Disease Progression; DNA; DNA Methylation; Female; Gene Silencing; Humans; Microsatellite Repeats; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Proportional Hazards Models; Random Allocation; Recurrence; Time Factors; Treatment Outcome | 2004 |
Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate | 2004 |
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.
Topics: Angina Pectoris; Antineoplastic Agents; Area Under Curve; Coronary Angiography; Coronary Disease; Coronary Restenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Paclitaxel; Recurrence; Stents; Treatment Outcome | 2005 |
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Heart Diseases; Humans; Mastectomy; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Recurrence; Survival Analysis; Trastuzumab | 2005 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Recurrence; Topotecan; Treatment Outcome | 2006 |
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Disease Progression; DNA Mutational Analysis; Exons; Female; Genotype; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Recurrence; Treatment Outcome | 2006 |
Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis -- safety assessment.
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Restenosis; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Injections, Intralesional; Male; Middle Aged; Paclitaxel; Recurrence; Stents; Treatment Outcome | 2006 |
Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings.
Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Ploidies; Radiation Dosage; Radiation-Sensitizing Agents; Recurrence; Risk Factors; Treatment Failure | 2006 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Stem Cells; Time Factors; Vinblastine; Vinorelbine | 2006 |
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Female; Fever; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Rate | 2007 |
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
Topics: Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cohort Studies; Coronary Restenosis; Electrocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Prospective Studies; Recurrence; Registries; Retrospective Studies; Sirolimus; Stents; Survival Rate; Ticlopidine; Treatment Outcome | 2007 |
Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Selection; Radiotherapy; Recurrence; Survival Analysis; Survivors; Time Factors | 2007 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Recurrence; Testicular Neoplasms | 2008 |
Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Recurrence; Stomach Neoplasms; Survival Analysis | 2009 |
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence | 2008 |
Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Coronary Vessel Anomalies; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Prospective Studies; Prosthesis Implantation; Recurrence; Sirolimus; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Multiple; Female; Humans; Infusions, Parenteral; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Palliative Care; Polymerase Chain Reaction; Recurrence; RNA, Messenger | 1995 |
Radiation-recall dermatitis in a patient treated with paclitaxel.
Topics: Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence | 1995 |
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Alopecia; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Remission Induction | 1995 |
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cross-Over Studies; Cyclosporine; Dexamethasone; Dextropropoxyphene; Diphenhydramine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Paclitaxel; Premedication; Recurrence; Remission Induction | 1996 |
A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome | 1996 |
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
Topics: Adult; Aged; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome | 1997 |
An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence; Survival Rate; Uterine Cervical Neoplasms | 1997 |
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate | 1998 |
A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Quinine; Recurrence | 1998 |
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intradermal; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome | 1998 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Survival Rate; Treatment Outcome | 1999 |
Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Humans; Lymphoma; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate | 1999 |
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Recurrence; Thiotepa; Transplantation, Autologous; Treatment Outcome | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Paclitaxel; Recurrence; Taxoids; Time Factors; Treatment Outcome | 1999 |
Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Safety; Time Factors; Vinblastine; Vinorelbine | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Evaluation; Female; Hemorrhage; Humans; Infections; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Recurrence; Survival Rate; Treatment Outcome | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Greece; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Survival Rate | 2001 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cohort Studies; Combined Modality Therapy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fallopian Tube Neoplasms; Female; Genes, p53; Genetic Therapy; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tomography, X-Ray Computed; Transgenes | 2002 |
182 other study(ies) available for paclitaxel and Recrudescence
| Article | Year |
|---|---|
Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.
Topics: Adamantane; Animals; Antineoplastic Agents; Constriction, Pathologic; Iliac Artery; In Vitro Techniques; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Donors; Nitroso Compounds; Paclitaxel; Platelet Aggregation Inhibitors; Rabbits; Recurrence; Stents; Vascular Diseases | 2004 |
Early-phase restenosis following directional coronary atherectomy and paclitaxel-coated balloon angioplasty: a histopathological analysis.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Coronary Angiography; Coronary Restenosis; Humans; Paclitaxel; Recurrence; Treatment Outcome | 2023 |
Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Atherectomy; California; Cardiovascular Agents; Coated Materials, Biocompatible; Colorado; Constriction, Pathologic; Female; Femoral Artery; Humans; Laser Therapy; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Databases, Factual; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Drug-Coated Balloon Dilation Compared With Conventional Stenting Angioplasty for Intracranial Atherosclerotic Disease.
Topics: Aged; Angioplasty, Balloon; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Stents; Treatment Outcome | 2020 |
Combination of Percutaneous Rotational Thrombectomy and Drug-Coated Balloon for Treatment of Femoropopliteal Artery Nonembolic Occlusion: 12-Month Follow-up.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Beijing; Cardiovascular Agents; Female; Femoral Artery; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Risk Factors; Thrombectomy; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2020 |
Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Topics: Aged; Aged, 80 and over; Datasets as Topic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2021 |
Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Bevacizumab; CA-125 Antigen; Carbamates; Carboplatin; Cystadenocarcinoma, Serous; Disease Progression; Everolimus; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; MAP Kinase Kinase 1; Medroxyprogesterone; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oximes; Paclitaxel; Progression-Free Survival; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Recurrence; Sulfonamides; Tamoxifen; Treatment Outcome; Young Adult | 2020 |
A Multicenter Global Registry of Paclitaxel Drug-Coated Balloon in Dysfunctional Arteriovenous Fistulae and Grafts: 6-Month Results.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Asia; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Europe; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Paclitaxel; Prospective Studies; Recurrence; Registries; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
The Real-World CONSEQUENT ALL COMERS Study: Predictors for Target Lesion Revascularization and Mortality in an Unselected Patient Population.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Cause of Death; Coated Materials, Biocompatible; Europe; Female; Femoral Artery; Humans; Malaysia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Resveratrol; Risk Assessment; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic; Popliteal Artery; Prospective Studies; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Impact of Fluoropolymer-Based Paclitaxel Delivery on Neointimal Proliferation and Vascular Healing: A Comparative Peripheral Drug-Eluting Stent Study in the Familial Hypercholesterolemic Swine Model of Femoral Restenosis.
Topics: Angiography; Animals; Cardiovascular Agents; Cell Proliferation; Constriction, Pathologic; Disease Models, Animal; Drug-Eluting Stents; Endovascular Procedures; Femoral Artery; Hyperlipoproteinemia Type II; Methacrylates; Neointima; Paclitaxel; Peripheral Arterial Disease; Polymers; Polyvinyls; Prosthesis Design; Recurrence; Sus scrofa; Time Factors; Tomography, Optical Coherence; Vascular Patency; Wound Healing | 2017 |
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Mice; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Catheters; Cardiovascular Agents; Case-Control Studies; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Metals; Middle Aged; Odds Ratio; Paclitaxel; Percutaneous Coronary Intervention; Prospective Studies; Prosthesis Design; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome | 2017 |
Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antineoplastic Agents, Phytogenic; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Non-ST Elevated Myocardial Infarction; Paclitaxel; Percutaneous Coronary Intervention; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Sirolimus; ST Elevation Myocardial Infarction; Treatment Outcome | 2017 |
A universal drug delivery catheter for the treatment of infrapopliteal arterial disease: Results from the multi-center first-in-human study.
Topics: Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Catheterization, Peripheral; Constriction, Pathologic; Feasibility Studies; Female; Humans; Limb Salvage; Lower Extremity; Male; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; United States; Vascular Access Devices; Vascular Patency | 2018 |
[Nearly Complete Response after Second-Line Therapy with Nab-Paclitaxel Monotherapy in a Patient with Recurrent Advanced Non-Small Cell Lung Cancer].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Paclitaxel; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
Topics: Aged; Amputation, Surgical; Angiography; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Endovascular Procedures; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2017 |
Freeway paclitaxel-releasing balloons to treat recurrent stenosis of arteriovenous fistula in hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Fistula; Constriction, Pathologic; Endovascular Procedures; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Recurrence; Renal Dialysis; Time Factors; Young Adult | 2018 |
[A Case of Recurrent Gastric Cancer with Grade 3 Proteinuria Caused by Ramucirumab plus Paclitaxel Therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Gastrectomy; Humans; Paclitaxel; Proteinuria; Ramucirumab; Recurrence; Stomach Neoplasms | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
Topics: Aged; Alloys; Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Self Expandable Metallic Stents; Time Factors; Treatment Outcome; Vascular Patency | 2018 |
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Paclitaxel; Recurrence; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2018 |
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult | 2018 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
1-Year All-Comers Analysis of the Eluvia Drug-Eluting Stent for Long Femoropopliteal Lesions After Suboptimal Angioplasty.
Topics: Aged; Angioplasty; Cardiovascular Agents; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Calcification; Vascular Patency | 2018 |
[Paclitaxel-coated balloons for in-stent restenosis treatment: long-term clinical results and predictors of recurrent target lesion revascularization].
Topics: Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Female; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Assessment; Treatment Outcome; Vascular Patency | 2018 |
[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Furans; Humans; Ketones; Paclitaxel; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2018 |
Angiosarcoma-related pneumohemothorax treated with intrapleural paclitaxel administration and pleurodesis with OK-432.
Topics: Aged; Antineoplastic Agents; Fatal Outcome; Hemangiosarcoma; Hemothorax; Humans; Male; Paclitaxel; Picibanil; Pleural Neoplasms; Pleurodesis; Pneumothorax; Recurrence; Skin Neoplasms | 2018 |
[Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies | 2018 |
The Efficacy of Paclitaxel Drug-Eluting Balloon Angioplasty Versus Standard Balloon Angioplasty in Stenosis of Native Hemodialysis Arteriovenous Fistulas: An Analysis of Clinical Success, Primary Patency and Risk Factors for Recurrent Dysfunction.
Topics: Angioplasty; Angioplasty, Balloon; Arteriovenous Fistula; Female; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Renal Dialysis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tubulin Modulators; Vascular Patency | 2019 |
One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Europe; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Registries; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Grading; Oncogene Proteins, Fusion; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Recurrence; Transcription, Genetic | 2019 |
Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Cardiovascular Agents; Cilostazol; Constriction, Pathologic; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Prosthesis Design; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Vascular Calcification; Vascular Patency | 2019 |
Two Years Efficacy of Paclitaxel-Coated Balloon Dilation for In-Stent Renal Artery Restenosis Due to Takayasu Arteritis.
Topics: Angioplasty, Balloon; Coated Materials, Biocompatible; Female; Humans; Paclitaxel; Recurrence; Renal Artery Obstruction; Stents; Takayasu Arteritis; Young Adult | 2019 |
Combination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report.
Topics: Adolescent; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Paclitaxel; Polyethylene Glycols; Recurrence; Treatment Outcome | 2013 |
2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Exercise Test; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Quality of Life; Recurrence; Registries; Stents; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2013 |
How should I treat a restenosis after superficial femoral artery stenting?
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Humans; Male; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Recurrence; Stents; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler; Vascular Access Devices | 2013 |
[Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients].
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence; Tomography, X-Ray Computed | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
[A patient with recurrent ovarian clear cell adenocarcinoma and chronic kidney disease exhibited complete response to paclitaxel plus carboplatin].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Paclitaxel; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
[A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Taxoids; Tegafur | 2013 |
[A case of solitary adrenal metastasis from breast cancer successfully resected by laparoscopy].
Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Laparoscopy; Middle Aged; Paclitaxel; Recurrence; Trastuzumab | 2013 |
[A case of recurrent breast cancer with carcinomatous pleurisy responding to bevacizumab and paclitaxel therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pleurisy; Recurrence | 2013 |
[A patient with thyroid cancer evaluated according to Response Evaluation Criteria in Solid Tumors during treatment for breast cancer recurrence in hepatic and cervical lymph nodes].
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Diagnosis, Differential; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Neck; Paclitaxel; Recurrence; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Recurrence; Snail Family Transcription Factors; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Efficacy of supportive care for albumin-bound paclitaxel(nab-paclitaxel)in 20 patients with metastatic breast cancer].
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Recurrence | 2014 |
[A case of peritoneal carcinomatosis due to recurrence of primary adenocarcinoma of the ureter treated with weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Urologic Neoplasms | 2014 |
Association between high antitumor activity of oxaliplatin and cyclophosphamide and constitutional GSTM1 homozygous deletion in an advanced ovarian cancer patient.
Topics: Alleles; Antineoplastic Agents; Carboplatin; Cyclophosphamide; Female; Gene Deletion; Glutathione Transferase; Homozygote; Humans; Hypersensitivity; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Recurrence | 2013 |
Neoatherosclerosis after paclitaxel-coated balloon angioplasty for in-stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Tubulin Modulators; Ultrasonography | 2014 |
Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Femoral Artery; Follow-Up Studies; Humans; Italy; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Recurrence; Registries; Retreatment; Stents; Time Factors; Treatment Outcome; Vascular Access Devices | 2014 |
Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
Topics: Aged; Aged, 80 and over; Alloys; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Time Factors; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2014 |
Paclitaxel for relapsed or recurrent HIV-associated pediatric Kaposi's sarcoma.
Topics: Antineoplastic Agents, Phytogenic; Child; HIV Infections; Humans; Male; Paclitaxel; Radiography, Thoracic; Recurrence; Sarcoma, Kaposi; Treatment Outcome | 2014 |
A case of relapsed visceral Kaposi's sarcoma with bilateral chylothoraces successfully treated with paclitaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Chylothorax; HIV Infections; Humans; Male; Paclitaxel; Recurrence; Sarcoma, Kaposi; Treatment Outcome | 2015 |
Long-term results of drug-eluting balloon angioplasty for treatment of refractory recurrent carotid in-stent restenosis.
Topics: Aged; Angioplasty, Balloon; Blood Flow Velocity; Cardiovascular Agents; Carotid Stenosis; Drug-Eluting Stents; Endovascular Procedures; Female; Humans; Hyperplasia; Male; Middle Aged; Neointima; Paclitaxel; Prosthesis Design; Recurrence; Regional Blood Flow; Retreatment; Risk Factors; Stents; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler; Vascular Patency | 2014 |
Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
[Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence | 2014 |
Solving the Issue of Restenosis After Stenting of Intracranial Stenoses: Experience with Two Thin-Strut Drug-Eluting Stents (DES)-Taxus Element™ and Resolute Integrity™.
Topics: Aged; Drug-Eluting Stents; Equipment Design; Female; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Stroke; Treatment Outcome | 2015 |
Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Femoral Artery; Humans; Japan; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2016 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
[Prolonged remission achieved by using bevacizumab plus paclitaxel therapy combined with sequential radiotherapy for a rapidly growing chest wall recurrence of triple negative breast cancer - a case report].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Disease Progression; Female; Humans; Mastectomy, Modified Radical; Paclitaxel; Recurrence; Remission Induction; Thoracic Wall; Triple Negative Breast Neoplasms | 2015 |
Everolimus-eluting stent implantation versus repeat paclitaxel-coated balloon angioplasty for recurrent in-stent restenosis lesion caused by paclitaxel-coated balloon failure.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Everolimus; Female; Humans; Male; Paclitaxel; Prosthesis Design; Recurrence; Sirolimus; Treatment Outcome | 2015 |
Paclitaxel-eluting balloon dilation of biliary anastomotic stricture after liver transplantation.
Topics: Adult; Catheters; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Coated Materials, Biocompatible; Constriction, Pathologic; Equipment Design; Feasibility Studies; Female; Germany; Hospitals, University; Humans; Liver Transplantation; Male; Middle Aged; Paclitaxel; Pilot Projects; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2015 |
[Nanoparticle albumin-bound Paclitaxel for unresectable or recurrent gastric cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Female; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Stomach Neoplasms | 2014 |
Association between tissue characteristics assessed with optical coherence tomography and mid-term results after percutaneous coronary intervention for in-stent restenosis lesions: a comparison between balloon angioplasty, paclitaxel-coated balloon dilata
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Percutaneous Coronary Intervention; Recurrence; Reproducibility of Results; Severity of Illness Index; Stents; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Paclitaxel-coated balloon angioplasty for symptomatic central vein restenosis in patients with hemodialysis fistulas.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriovenous Shunt, Surgical; Cardiovascular Agents; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Recurrence; Renal Dialysis; Reoperation; Retrospective Studies; Time Factors; Treatment Outcome; Upper Extremity Deep Vein Thrombosis | 2015 |
Valvuloplasty with a paclitaxel-eluting balloon prevents restenosis in an experimental animal model of aortic stenosis.
Topics: Animals; Aortic Valve Stenosis; Atherosclerosis; Balloon Valvuloplasty; Calcinosis; Calcium; Disease Models, Animal; Paclitaxel; Proliferating Cell Nuclear Antigen; Rabbits; Random Allocation; Recurrence; Ultrasonography; X-Ray Microtomography | 2014 |
Drug-coated balloon dilation before carotid artery stenting of post-carotid endarterectomy restenosis.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Carotid Stenosis; Coated Materials, Biocompatible; Endarterectomy, Carotid; Equipment Design; Female; Humans; Italy; Male; Paclitaxel; Recurrence; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2015 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Area Under Curve; Blood Flow Velocity; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Drug-Eluting Stents; Female; Femoral Artery; Humans; Ischemia; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Predictive Value of Tests; Prosthesis Design; Radiography; Recurrence; Regional Blood Flow; Retrospective Studies; Risk Factors; ROC Curve; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional | 2015 |
[Efficacy of balloon catheters with antiproliferative cover in patients with impairment of arteries of femoral-popliteal segment].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Coated Materials, Biocompatible; Constriction, Pathologic; Cytostatic Agents; Femoral Artery; Humans; Paclitaxel; Popliteal Artery; Recurrence; Treatment Outcome; Vascular Access Devices | 2015 |
Drug-Eluting vs Standard Balloon Angioplasty for Iliac Stent Restenosis: Midterm Results.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Humans; Iliac Artery; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Radiography; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Vascular Access Devices; Vascular Patency | 2015 |
1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Japan; Kaplan-Meier Estimate; Linear Models; Male; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Radiography; Recurrence; Risk Factors; Thrombosis; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2015 |
Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Paclitaxel; Recurrence; Retrospective Studies | 2015 |
[A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Paclitaxel and Bevacizumab after Radical Mastectomy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Mastectomy, Radical; Middle Aged; Paclitaxel; Pleurisy; Recurrence | 2015 |
[A CASE OF UROTHELIAL CARCINOMA OF THE URINARY BLADDER WITH SQUAMOUS DIFFERENTIATION RESPONDING TO PACLITAXEL AND CARBOPLATIN NEOADJUVANT CHEMOTHERAPY].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Fatal Outcome; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Recurrence; Tomography, X-Ray Computed; Urethral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2015 |
Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Critical Illness; Diabetic Angiopathies; Drug-Eluting Stents; Female; Femoral Artery; Historically Controlled Study; Humans; Ischemia; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Retreatment; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Evaluation of the Biodegradable Igaki-Tamai Scaffold After Drug-Eluting Balloon Treatment of De Novo Superficial Femoral Artery Lesions: The GAIA-DEB Study.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon; Ankle Brachial Index; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Retreatment; Surveys and Questionnaires; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Access Devices; Vascular Patency | 2016 |
[A Case of Lymph Node Metastases from Esophageal Cancer Successfully Treated with Weekly Paclitaxel Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Esophageal Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence | 2015 |
Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
Topics: Aged; Amputation, Surgical; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Topics: Aged; Aged, 80 and over; Alloys; Angiography; Angioplasty, Balloon; Area Under Curve; Cardiovascular Agents; Chi-Square Distribution; Constriction, Pathologic; Drug-Eluting Stents; Female; Femoral Artery; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Peripheral Arterial Disease; Predictive Value of Tests; Prosthesis Design; Recurrence; Retrospective Studies; Risk Factors; ROC Curve; Stents; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2016 |
Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
Topics: Biomarkers, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Models, Biological; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Prognosis; Recurrence; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Single-Center Experience With Lutonix Drug-Coated Balloons in Infrapopliteal Arteries.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Germany; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clone Cells; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Paclitaxel; Recurrence; Ribonucleoproteins, Small Nuclear; RNA, Messenger; Single-Cell Analysis; Spliceosomes; Transcriptome | 2016 |
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Recurrence; Taxoids; Trastuzumab; Treatment Outcome | 2016 |
Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Metals; Middle Aged; Multivariate Analysis; Paclitaxel; Popliteal Artery; Proportional Hazards Models; Prosthesis Design; Prosthesis Failure; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2017 |
Incidence and its characteristics of repetition of reintervention after drug-eluting stent implantation for femoropopliteal lesion.
Topics: Aged; Aged, 80 and over; Angiography; Cardiovascular Agents; Critical Illness; Databases, Factual; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Incidence; Ischemia; Japan; Kaplan-Meier Estimate; Male; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Proportional Hazards Models; Prosthesis Design; Recurrence; Retreatment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2016 |
[A Case of Recurrent Breast Cancer with Carcinomatous Pleurisy Successfully Treated with Biweekly Paclitaxel and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Paclitaxel; Pleurisy; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Neoatherosclerosis after paclitaxel-eluting stent implantation: Ex vivo intravascular image and histopathology.
Topics: Aged; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Paclitaxel; Recurrence; Tubulin Modulators; Tunica Intima | 2017 |
Comparison of Drug-Eluting Balloon and Standard Balloon Angioplasty for Infrapopliteal Arterial Diseases in Diabetic Patients.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Chi-Square Distribution; Coated Materials, Biocompatible; Diabetic Angiopathies; Equipment Design; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Turkey; Vascular Access Devices; Vascular Patency | 2016 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
Successful revascularization of re-stenosis of lower extremity arteries with localized delivery of paclitaxel.
Topics: Aged; Angiography; Angioplasty, Balloon; Arterial Occlusive Diseases; Atherectomy; Female; Humans; Leg; Male; Middle Aged; Paclitaxel; Recurrence; Stents; Ultrasonography, Interventional | 2008 |
[A case of recurrent breast cancer with bone marrow metastasis treated with weekly paclitaxel therapy].
Topics: Adult; Biomarkers, Tumor; Biopsy; Bone Marrow Neoplasms; Breast Neoplasms; Female; Humans; Paclitaxel; Radiography; Recurrence; Time Factors; Treatment Failure | 2008 |
Drug-eluting stent insertion in the treatment of in-stent renal artery restenosis in three renal transplant recipients.
Topics: Adult; Aged; Angioplasty, Balloon; Cardiovascular Agents; Drug-Eluting Stents; Female; Humans; Kidney Transplantation; Magnetic Resonance Angiography; Male; Metals; Middle Aged; Paclitaxel; Prosthesis Design; Radiography; Recurrence; Renal Artery Obstruction; Stents; Treatment Outcome; Vascular Patency | 2008 |
Recalcitrant in-stent restenosis of the celiac trunk treated by drug-eluting stent.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Celiac Artery; Chronic Disease; Constriction, Pathologic; Drug-Eluting Stents; Female; Humans; Ischemia; Magnetic Resonance Angiography; Mesenteric Vascular Occlusion; Metals; Paclitaxel; Prosthesis Design; Recurrence; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Fracture of a paclitaxol-eluting stent implanted for in-stent restenosis at the site of sirolimus-eluting stent fracture.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Occlusion; Coronary Restenosis; Drug-Eluting Stents; Humans; Immunosuppressive Agents; Male; Myocardial Infarction; Paclitaxel; Prosthesis Failure; Recurrence; Retreatment; Sirolimus | 2010 |
Long-term outcomes of left main coronary intervention with drug-eluting stents.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Recurrence; Sirolimus; Treatment Outcome | 2009 |
Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease.
Topics: Aged; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Paclitaxel; Proportional Hazards Models; Recurrence; Sirolimus; Treatment Outcome | 2009 |
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recurrence; Retrospective Studies; Treatment Outcome | 2009 |
Sensory polyneuropathy associated with paclitaxel-eluting coronary stent.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon; Coronary Restenosis; Disease Susceptibility; Drug-Eluting Stents; Humans; Male; Neural Conduction; Paclitaxel; Paresthesia; Polyneuropathies; Recurrence; Sensation Disorders; Sjogren's Syndrome | 2009 |
[A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Long-term clinical outcome of chronic total occlusive lesions treated with drug-eluting stents: comparison of sirolimus-eluting and paclitaxel-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cohort Studies; Coronary Angiography; Coronary Occlusion; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Recurrence; Registries; Sirolimus; Treatment Failure; Treatment Outcome | 2010 |
Drug-eluting stents versus bare-metal stents in acute ST-segment elevation myocardial infarction. a single-center experience with long-term follow up.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cohort Studies; Coronary Angiography; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Prosthesis Design; Recurrence; Retrospective Studies; Sirolimus; Treatment Outcome | 2010 |
Drug-eluting stent versus bare-metal stent in acute ST-segment elevation myocardial infarction: a word of caution.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cohort Studies; Coronary Restenosis; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Metals; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Postoperative Care; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Recurrence; Retreatment; Risk Assessment; Sirolimus; Survival Analysis; Treatment Outcome | 2010 |
[Successful management with S-1 of recurrent gastric cancer after adjuvant chemotherapy with paclitaxel/UFT].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Diabetes Complications; Drug-Eluting Stents; Female; Heart Diseases; Humans; Korea; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Assessment; Risk Factors; Sirolimus; Time Factors; Treatment Outcome | 2010 |
Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Mammography; Neoplasm Metastasis; Paclitaxel; Prognosis; Prospective Studies; Recurrence; Risk; Treatment Outcome | 2010 |
[A case of breast cancer with multiple hepatic metastasis successfully treated with S-1/PTX and S-1 chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Combinations; Female; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Tegafur; Tomography, X-Ray Computed | 2010 |
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Polyethylene Glycols; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
[A case of mammary Paget's disease with early systemic recurrence after operation].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Paclitaxel; Paget's Disease, Mammary; Recurrence; Time Factors; Tomography, X-Ray Computed; Trastuzumab | 2010 |
[A case of recurrent cholangiocarcinoma responding to weekly paclitaxel].
Topics: Aged; CA-19-9 Antigen; Cholangiocarcinoma; Humans; Male; Paclitaxel; Recurrence; Salvage Therapy; Tomography, X-Ray Computed | 2010 |
Very late restenosis of a paclitaxel-eluting stent implanted to treat previous in-stent restenosis of a bare metal stent.
Topics: Aged; Coronary Restenosis; Drug-Eluting Stents; Humans; Male; Paclitaxel; Prosthesis Design; Recurrence; Stents; Time Factors | 2010 |
Drug-eluting tibial stents: objective patency determination.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Drug-Eluting Stents; Female; Humans; Ischemia; Life Tables; Limb Salvage; Male; Middle Aged; Minnesota; Paclitaxel; Platelet Aggregation Inhibitors; Prosthesis Design; Radiography; Recurrence; Reoperation; Retrospective Studies; Severity of Illness Index; Tibial Arteries; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vascular Patency | 2010 |
Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; DNA Copy Number Variations; ErbB Receptors; Female; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paclitaxel; Pneumonectomy; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Protein Array Analysis; Recurrence | 2011 |
Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Agents; Drug-Eluting Stents; Evidence-Based Medicine; Humans; Metals; Myocardial Infarction; Paclitaxel; Prosthesis Design; Recurrence; Risk Assessment; Risk Factors; Sirolimus; Stents; Thrombosis; Time Factors; Treatment Outcome | 2011 |
Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Chi-Square Distribution; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Metals; Myocardial Infarction; North Carolina; Paclitaxel; Propensity Score; Proportional Hazards Models; Prospective Studies; Prosthesis Design; Recurrence; Registries; Risk Assessment; Risk Factors; Sirolimus; Stents; Thrombosis; Time Factors; Treatment Outcome | 2011 |
Early-stage ovarian cancer management: still a challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Combined Modality Therapy; Female; Gynecologic Surgical Procedures; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recurrence; Treatment Outcome | 2011 |
Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: a case report.
Topics: Antineoplastic Agents; Carcinoembryonic Antigen; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Salvage Therapy; Stomach Neoplasms; Taxoids | 2011 |
Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial.
Topics: Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Saphenous Vein | 2011 |
Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab.
Topics: Adult; Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Fluorescein Angiography; Humans; Injections, Intravenous; Macular Edema; Paclitaxel; Recurrence; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2011 |
Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection.
Topics: Angiography; Angioplasty, Balloon, Coronary; Drug-Eluting Stents; Everolimus; Follow-Up Studies; Humans; Immunosuppressive Agents; Infant, Newborn; Male; Paclitaxel; Pulmonary Veins; Pulmonary Veno-Occlusive Disease; Recurrence; Sirolimus | 2011 |
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Confidence Intervals; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Reproducibility of Results; Time Factors | 2011 |
Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Topics: Aged; Alloys; Arterial Occlusive Diseases; Canada; Cardiovascular Agents; Constriction, Pathologic; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Europe; Female; Femoral Artery; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Recovery of Function; Recurrence; Republic of Korea; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2011 |
Multimodal treatment for multistation mediastinal lymph node adenocarcinoma: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; Cisplatin; Humans; Immunohistochemistry; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Multimodal Imaging; Neoplasms, Unknown Primary; Paclitaxel; Positron-Emission Tomography; Recurrence; Reoperation; Thoracoscopy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results.
Topics: Adult; Aged; Aged, 80 and over; Alloys; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Drug Delivery Systems; Equipment Design; Female; Femoral Artery; Humans; Italy; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Prosthesis Design; Recurrence; Registries; Stents; Time Factors; Treatment Outcome | 2011 |
Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies | 2012 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
[Prolonged complete response obtained by radiation and chemotherapy with paclitaxel in a case of recurrent gastric cancer in the rectovesical pouch].
Topics: Aged; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Humans; Male; Neoplasm Staging; Paclitaxel; Recurrence; Remission Induction; Retroperitoneal Neoplasms; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2011 |
Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.
Topics: Aged; Angioplasty, Balloon; Ankle Brachial Index; Arterial Occlusive Diseases; Cardiovascular Agents; Catheters; Chi-Square Distribution; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Paclitaxel; Popliteal Artery; Prospective Studies; Quality of Life; Recovery of Function; Recurrence; Registries; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency; Walking | 2012 |
Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Recurrence | 2013 |
[Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed; Trastuzumab | 2012 |
Drug-eluting balloon angioplasty for carotid in-stent restenosis.
Topics: Aged; Angiography, Digital Subtraction; Angioplasty, Balloon; Cardiovascular Agents; Carotid Arteries; Carotid Stenosis; Catheters; Coated Materials, Biocompatible; Drug Therapy, Combination; Equipment Design; Female; Humans; Male; Paclitaxel; Platelet Aggregation Inhibitors; Recurrence; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional; Vascular Patency | 2012 |
Drug-eluting balloon for treatment of in-stent restenosis after carotid artery stenting: preliminary report.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Carotid Artery, Common; Carotid Artery, Internal; Carotid Stenosis; Catheters; Coated Materials, Biocompatible; Equipment Design; Female; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Severity of Illness Index; Stents; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Ultrasonography, Interventional; Vascular Patency | 2012 |
[A case report of complete response by weekly paclitaxel and 5'-DFUR combination chemotherapy for recurrenced gastric cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Floxuridine; Gastrectomy; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms | 2012 |
Human internal mammary artery organ culture model of coronary stenting: a novel investigation of smooth muscle cell response to drug-eluting stents.
Topics: Cell Division; Coated Materials, Biocompatible; Coronary Artery Disease; Drug Delivery Systems; Graft Occlusion, Vascular; Humans; Mammary Arteries; Models, Cardiovascular; Muscle, Smooth, Vascular; Organ Culture Techniques; Paclitaxel; Phosphorylcholine; Recurrence; Stents | 2002 |
Radiation recall dermatitis from docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Paclitaxel; Radiodermatitis; Radiotherapy, Adjuvant; Recurrence; Taxoids | 2002 |
Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Constriction, Pathologic; Drug Administration Schedule; Female; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2003 |
Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model.
Topics: Administration, Oral; alpha-Tocopherol; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Carotid Artery Injuries; Carotid Stenosis; Catheterization; Cell Division; Ethylene Glycols; Glycerol; Hyperplasia; Infusions, Parenteral; Intestines; Linoleic Acids; Male; Models, Animal; Myocytes, Smooth Muscle; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Radiography; Rats; Rats, Sprague-Dawley; Recurrence; Surface-Active Agents; Tocopherols; Tunica Intima; Verapamil | 2004 |
Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Brachytherapy; Cohort Studies; Combined Modality Therapy; Coronary Restenosis; Coronary Stenosis; Disease-Free Survival; Drug Implants; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Male; Middle Aged; Paclitaxel; Radiography; Recurrence; Sirolimus; Stents; Treatment Outcome | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
The effects of paclitaxel on the three phases of restenosis: smooth muscle cell proliferation, migration, and matrix formation: an in vitro study.
Topics: Angioplasty, Balloon; Arteries; Cell Cycle; Cell Division; Cell Movement; Cells, Cultured; Colony-Forming Units Assay; Constriction, Pathologic; Dose-Response Relationship, Drug; Humans; Muscle, Smooth, Vascular; Paclitaxel; Recurrence; Tenascin | 2004 |
In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy Dosage; Recurrence; Topotecan | 2004 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Drug-eluting stents for the treatment of in-stent restenosis--'real world' double centre experience in consecutive patients.
Topics: Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Coronary Restenosis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Prosthesis Design; Recurrence; Retrospective Studies; Sirolimus; Stents; Time Factors; Treatment Outcome | 2005 |
Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
Topics: Coronary Angiography; Coronary Restenosis; Databases as Topic; Diabetes Mellitus; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Paclitaxel; Recurrence; Risk Factors; Sirolimus; Stents | 2006 |
Drug-eluting stent implantation for treatment of recurrent renal artery in-stent restenosis.
Topics: Angiography; Angioplasty, Balloon; Drug Delivery Systems; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Renal Artery Obstruction; Stents; Treatment Outcome; Ultrasonography, Interventional; Vascular Patency | 2006 |
Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation.
Topics: Anticoagulants; Aortic Dissection; Calcinosis; Carotid Artery, External; Carotid Artery, Internal; Carotid Stenosis; Catheterization; Cohort Studies; Drug Evaluation; Drug Implants; Feasibility Studies; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; Middle Aged; Organ Specificity; Paclitaxel; Recurrence; Retrospective Studies; Sirolimus; Stents; Stroke; Vertebrobasilar Insufficiency | 2006 |
Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
Topics: Coronary Angiography; Coronary Stenosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Stents; Survival Rate; Treatment Outcome; Tubulin Modulators; Ultrasonography, Interventional | 2006 |
Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries.
Topics: Actins; Animals; Apoptosis; Atherosclerosis; Cell Proliferation; Collagen; Drug Implants; Femoral Artery; Image Interpretation, Computer-Assisted; In Situ Nick-End Labeling; Male; Mice; Mice, Mutant Strains; Models, Animal; Muscle, Smooth, Vascular; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Stents; Tunica Intima | 2007 |
[Paclitaxel-induced lupus].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antineoplastic Agents, Phytogenic; Betamethasone; Biopsy; Drug Therapy, Combination; Erythropoietin; Female; Humans; Lupus Erythematosus, Cutaneous; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Recurrence; Skin; Treatment Outcome | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Treatment of restenosis after bare-metal and drug-eluting stenting of an aorto-ostial lesion: challenges associated with excessive stent overhang.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Drug Delivery Systems; Humans; Immunosuppressive Agents; Male; Paclitaxel; Recurrence; Reoperation; Sirolimus; Stents | 2007 |
The Emperor's new clothes: another cypher versus taxus post-hoc meta-analysis.
Topics: Blood Vessel Prosthesis; Coronary Artery Disease; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunosuppressive Agents; Meta-Analysis as Topic; Outcome and Process Assessment, Health Care; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Sirolimus; Stents; Treatment Outcome; Tubulin Modulators | 2007 |
Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Laryngeal Nerves; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Vinblastine; Vinorelbine; Vocal Cord Paralysis | 2008 |
Percutaneous unprotected left main angioplasty with drug-eluting stents in a nonagenarian: feasible and safe despite recurrent restenosis.
Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Feasibility Studies; Humans; Immunosuppressive Agents; Male; Paclitaxel; Radiography; Recurrence; Retreatment; Treatment Outcome; Tubulin Modulators | 2008 |
Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenoses 4 mm in diameter or smaller.
Topics: Aged; Aged, 80 and over; Angiography; Drug-Eluting Stents; Female; Gadolinium DTPA; Humans; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Recurrence; Renal Artery Obstruction; Retrospective Studies; Sirolimus; Stents; Treatment Outcome; Tubulin Modulators; Ultrasonography; Vascular Resistance | 2008 |
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow Diseases; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Receptors, Granulocyte Colony-Stimulating Factor; Recurrence | 1993 |
Primary central nervous system recurrence after paclitaxel therapy for epithelial ovarian malignancy.
Topics: Central Nervous System Neoplasms; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Remission Induction | 1994 |
Paclitaxel and radiation-recall dermatitis.
Topics: Adult; Female; Humans; Middle Aged; Paclitaxel; Radiation Tolerance; Radiodermatitis; Radiotherapy; Recurrence | 1994 |
Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation.
Topics: Catheterization, Central Venous; Drug Eruptions; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Recurrence | 1994 |
Recurrent breast cancer treated successfully with mitomycin-C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel--a case report.
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Female; Humans; Mitomycin; Paclitaxel; Radiography; Recurrence; Treatment Failure; Vinblastine | 1996 |
Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Agents; Hodgkin Disease; Humans; Middle Aged; Paclitaxel; Recurrence | 1996 |
A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Male; Middle Aged; Paclitaxel; Recurrence; Sarcoma; Soft Tissue Neoplasms | 1996 |
Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome | 1998 |
Prolonged remission of endometrial cancer with paclitaxel and carboplatin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Time Factors | 1998 |
Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol.
Topics: Actuarial Analysis; Adult; Aged; Brain; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Paclitaxel; Pilot Projects; Radiation-Sensitizing Agents; Radiosurgery; Recurrence; Retrospective Studies; Survival Analysis; Treatment Outcome | 1997 |
Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Platinum Compounds; Recurrence; Salvage Therapy; Treatment Outcome | 1998 |
Taxane-induced glaucoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Paclitaxel; Recurrence; Taxoids | 1999 |
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Constriction, Pathologic; Paclitaxel; Rabbits; Recurrence; Swine; Vascular Diseases | 2000 |
[Paclitaxel: a chemotherapeutic agent for prevention of restenosis? Experimental studies in vitro and in vivo].
Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Animals; Cell Division; Cell Movement; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Equipment Design; Humans; In Vitro Techniques; Paclitaxel; Rabbits; Recurrence; Stents; Swine; Vascular Patency | 2000 |
Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Recurrence; Taxoids | 2000 |
Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months.
Topics: Angiogenesis Inhibitors; Animals; Coronary Disease; Drug Delivery Systems; Paclitaxel; Rabbits; Recurrence; Stents; Time Factors; Tunica Intima | 2000 |
Oncologists scout new directions for KS and lymphoma therapies.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chorionic Gonadotropin; Female; Humans; Isotretinoin; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Mitoguazone; Paclitaxel; Palliative Care; Photochemotherapy; Recurrence; Sarcoma, Kaposi; Uterine Cervical Neoplasms | 1995 |
Successful treatment of an intractable case of hereditary basal cell carcinoma syndrome with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Basal Cell Nevus Syndrome; Humans; Male; Middle Aged; Neck; Paclitaxel; Recurrence; Scalp; Skin Neoplasms | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implants; Humans; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stents; Ticlopidine; Time Factors | 2001 |
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Topics: Adenoviridae; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Genes, p53; Genetic Therapy; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors | 2002 |
Simultaneous restenosis of Taxus and Cypher drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Cyperus; Drug Delivery Systems; Equipment Failure; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Plant Preparations; Recurrence; Retreatment; Risk Assessment; Severity of Illness Index; Stents; Taxus; Treatment Outcome; Vascular Patency | 2006 |
Intoxication with taxus baccata: cardiac arrhythmias following yew leaves ingestion.
Topics: Adult; Bradycardia; Electrocardiography; Fatal Outcome; Female; Heart Conduction System; Humans; Plant Leaves; Plant Poisoning; Recurrence; Suicide; Suicide, Attempted; Taxus; Ventricular Fibrillation | 2002 |